

Artificial MicroRNAs Targeting *C9orf72* Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients

Raygene Martier,^{1,2} Jolanda M. Liefhebber,¹ Jana Miniarikova,¹ Tom van der Zon,¹ Jolanda Snapper,¹ Iris Kolder,³ Harald Petry,¹ Sander J. van Deventer,^{1,2} Melvin M. Evers,¹ and Pavlina Konstantinova¹

¹Department of Research & Development, uniQure Biopharma B.V., Amsterdam, the Netherlands; ²Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, the Netherlands; ³BaseClear B.V., Sylviusweg 74, 2333 BE, Leiden, the Netherlands

The most common pathogenic mutation in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) is an intronic GGGGCC (G₄C₂) repeat in the chromosome 9 open reading frame 72 (*C9orf72*) gene. Cellular toxicity due to RNA foci and dipeptide repeat (DPR) proteins produced by the sense and antisense repeat-containing transcripts is thought to underlie the pathogenesis of both diseases.

RNA sequencing (RNA-seq) data of *C9orf72*-ALS patients and controls were analyzed to better understand the sequence conservation of *C9orf72* in patients. MicroRNAs were developed in conserved regions to silence *C9orf72* (miC), and the feasibility of different silencing approaches was demonstrated in reporter overexpression systems. In addition, we demonstrated the feasibility of a bidirectional targeting approach by expressing two concatenated miC hairpins. The efficacy of miC was confirmed by the reduction of endogenously expressed *C9orf72* mRNA, in both nucleus and cytoplasm, and an ~50% reduction of nuclear RNA foci in (G₄C₂)₄₄-expressing cells. Ultimately, two miC candidates were incorporated in adeno-associated virus vector serotype 5 (AAV5), and silencing of *C9orf72* was demonstrated in HEK293T cells and induced pluripotent stem cell (iPSC)-derived neurons. These data support the feasibility of microRNA (miRNA)-based and AAV-delivered gene therapy that could alleviate the gain of toxicity seen in ALS and FTD patients.

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease characterized by progressive degeneration of the upper and lower motor neurons, leading to muscle atrophy and paralysis. There is no disease-modifying therapy for ALS, and most patients die with respiratory failure within 3–5 years after the onset of symptoms.^{1–3} A significant number of ALS patients also develop frontotemporal dementia (FTD), a presenile dementia caused by progressive degeneration of the frontal and temporal lobes.^{3,4} The most common genetic cause of familial and sporadic ALS and FTD is an expanded GGGGCC (G₄C₂) repeat in the first intron of the chromosome 9 open reading frame 72 (*C9orf72*) gene.^{2,5} The G₄C₂ repeat in patients can be several hundred repeats long and is transcribed bidi-

rectionally.^{1,2} Generally, less than 30 repeats are considered non-pathogenic.^{1,2,6}

The G₄C₂ repeat is found in approximately 40% of familial ALS cases and 9% of sporadic ALS.^{7,8} The mechanisms underlying the involvement of *C9orf72* in neurodegeneration have been a debate for several years, with loss of function, gain of toxicity, or a combination of both being implicated.^{9,10} A reduction of *C9orf72* transcripts is detected in a significant number of *C9orf72*-ALS (C9-ALS) patients, supporting loss of function.^{8,11} However, complete elimination of *C9orf72* in mice causes immune system-related pathology but no motor deficits. These conditions were rescued in mice hemizygous for *C9orf72* that express 50% of *C9orf72* mRNA.^{12,13} In humans, a few loss-of-function mutations in *C9orf72* were identified and all seemed to be non-pathogenic, thus *C9orf72* reduction in humans is likely to be tolerable.¹⁴ Most evidence suggests that *C9orf72*-related pathogenicity is a result of gain of toxicity by the accumulation of sense and antisense RNA foci in the nucleus and deposition of dipeptide repeat (DPR) proteins in the cytoplasm.^{7,15–20} RNA foci can bind and sequester the function of RNA-binding proteins, leading to RNA-mediated toxicity.^{19,21} DPR proteins are linked to a variety of toxic effects.^{9,19,21} Thus, lowering the accumulation of RNA foci and DPR proteins is an attractive therapeutic strategy in ALS and FTD.

Directly targeting the G₄C₂ repeat to exclusively silence the repeat-containing transcripts is preferable but challenging, due to the high GC content, bidirectional transcription, intronic position, and nuclear localization.²² The repeat-containing transcripts are also poorly characterized, and sequence variations downstream of the G₄C₂ repeat region suggest that the area close to the repeat may not be well conserved between patients.²³

Received 19 September 2018; accepted 22 January 2019;
<https://doi.org/10.1016/j.omtn.2019.01.010>

Correspondence: Pavlina Konstantinova, Department of Research & Development, uniQure Biopharma B.V., P.O. 22506, 1100 DA, Amsterdam, the Netherlands.

E-mail: p.konstantinova@uniquere.com



Fully complementary anti-GGGGCC or anti-CCCCGG single-stranded small interfering RNAs (ss-siRNAs) reduced *C9orf72* sense and antisense foci.²⁴ Antisense oligonucleotides (ASOs) against *C9orf72* intron 1 near the G₄C₂ repeat also resulted in the reduction of sense RNA foci and DPR proteins, while the overall *C9orf72* levels were not affected.^{13,17,25} Interestingly, RNA foci and DPR proteins were also reduced by ASOs against exonic regions to target all *C9orf72* transcripts. Thus, both mutant-specific or total *C9orf72*-silencing approaches can lower RNA foci and DPR proteins.

The administration of synthetic siRNAs and ASOs is promising but requires repeated administration. We and others have reported that siRNAs derived from short hairpin RNA (shRNA) or microRNA (miRNA) scaffolds delivered with adeno-associated virus (AAV) vectors have the advantage of providing long-lasting therapeutic effects in different disease models of the CNS.^{26–29} High concentrations of shRNAs can bypass the nuclear RNase III Drosha processing and overload the cytoplasm with double-stranded RNA, leading to toxicity.³⁰ miRNAs are safer, as their precursors are encoded in the genome, thus mimicking the natural processing pathway. Moreover, the miRNA-expression cassette can be driven by RNA polymerase II (Pol II) or Pol III promoters, allowing for tissue- or cell-specific expression.

We here report on the development of therapeutic miRNAs (miC) as a proof of concept to silence *C9orf72* mRNA. We used a recently published RNA sequencing (RNA-seq) library from C9-ALS patients to investigate *C9orf72* expression and sequence composition for the identification of potential miC target sites in intron 1 and exonic regions.³¹ miC constructs were designed to target the sense, antisense, or both strands of *C9orf72*. The natural cellular primary (pri)-miR-101-1 and pri-miR-451 scaffolds were selected to embed the miC sequences, based on our previous findings that both scaffolds produced guide strands that were highly active.²⁹ pri-miRNAs are produced by Pol I or Pol II transcription, and they fold into hairpin-like scaffolds, which determine their further processing by the microprocessor complex.³² The tail of pri-miRNAs is cleaved by Drosha in the nucleus, generating a precursor miRNA (pre-miRNA) that is subsequently exported to the cytoplasm for further processing into a mature miRNA.^{33–35} The silencing efficacy of the miC-101 and miC-451 candidates was tested on luciferase (Luc) reporters, and it was confirmed with knockdown of the endogenously expressed *C9orf72* mRNA. The processing pattern was determined by next-generation sequencing (NGS).

One major challenge for an effective RNAi approach is the nuclear localization of the repeat-containing transcripts, as the mature miC is produced in the cytoplasm. Therefore, the expression and silencing efficacy of the miC candidates in both nucleus and cytoplasm was investigated, and we studied the ability of these constructs to silence nuclear RNA foci formation caused by G₄C₂ repeats. Finally, two candidates were selected and incorporated into AAV5 vector to test their efficacy *in vitro* on HEK293T cells and in frontal brain-like neurons generated from induced pluripotent stem cells (iPSCs) from an

FTD patient. The expression of total *C9orf72* (all *C9orf72* sense transcripts) was significantly reduced in both cell lines. Hence, our data provide evidence on the efficacy of artificial miRNAs against *C9orf72* as a promising AAV-based gene therapy for ALS and FTD.

RESULTS

Reduced *C9orf72* Levels Detected by RNA-Seq in C9-ALS Patients

The human *C9orf72* gene consists of 12 exons that can be transcribed in three different transcript variants (V1, V2, and V3) (Figure 1A). The G₄C₂ repeat in intron 1 is in the promoter region of V2 and the first intron of V1 and V3. We used a publicly available RNA-seq library to determine the expression of *C9orf72* in cerebellar and cortical tissues of 8 C9-ALS patients and 7 healthy controls.³¹ Notably, we found that *C9orf72* is more highly expressed (~2-fold) in the cerebellum compared to cortex in both C9-ALS patients and controls (Figure 1B). It was also found that *C9orf72* mRNA expression is consistently reduced in both cerebellum and cortex of C9-ALS patients. To determine if the reduction seen in C9-ALS patients is variant specific, we investigated the relative expressions of V1, V2, and V3 in patients and controls (Figure 1C). Expressions of V1, V2, and V3 were determined in percentages, relative to total (100%) *C9orf72* expression. In both cerebellum and cortex, the proportions of the variants in patients and controls were similar, suggesting that the reduction of *C9orf72* mRNA levels in C9-ALS patients is not variant specific.

Intronic Inclusions due to G₄C₂ Repeat Are Detected in C9-ALS Patients by RNA-Seq

C9orf72 intron 1 should be spliced out and degraded, but defective splicing may result in the accumulation of repeat-containing transcripts in the cell nucleus.³⁶ These repeat-containing transcripts are poorly characterized, and there is little information on the conservation of this region in C9-ALS patients. To address this question, read alignments from C9-ALS patients and controls were compared to investigate the sequence conservation of intronic and exonic regions of *C9orf72* transcripts (Figure 1D). The read depths in exon 1a, exon 1b, intron 1, exon 2, and exon 11 were estimated by correcting the total number of reads by the area size. We found a complete coverage of exon 2 to exon 11, though read depths in exon 1a, exon 1b, and intronic regions were very low in both C9-ALS and control groups. Exonic regions from exon 2 to exon 11 were less covered in patients, while the read depth for intron 1 in the patients was comparable with controls.

To estimate the relative coverage of the exons and introns, the ratio between the number of reads in C9-ALS patients and controls was determined (Figure 1E). All *C9orf72* exonic regions were about 2-fold lower expressed in C9-ALS patients. Intron 1 had the same number of reads in patient samples compared to controls, while introns 2–4 were 1.4 times higher in C9-ALS patients than controls. Introns 5–7 were excluded, as these could potentially be 3' UTR of the short *C9orf72* variant, and coverage of introns 8–10 was not increased in C9-ALS patients. Similarly, in the frontal cortex samples




Figure 1. *C9orf72* Expression and Target Regions

(A) Schematic of *C9orf72* gene and transcript variants. The G_4C_2 repeat is in intron 1 of transcript variants V1 and V3 and in the promoter region of V2. (B) *C9orf72* expression in C9-ALS patients and controls. *C9orf72* gene expression was determined from RNA-seq libraries in cerebellum and frontal cortex from 8 C9-ALS patients and 7 control donors. The mean expression values are shown in fragments per kilobase of transcript per million mapped reads (FPKM). (C) Relative expression of predicted *C9orf72* variants. The mRNA variants in C9-ALS and controls were predicted from the mapped and aligned RNA-seq data. Isoform V1 is predicted from read alignment from exon 1a to exon 5 (1,950 bp), isoform V2 from exon 1b to exon 11 (3,243 bp), and isoform V3 from exon 1a to exon 11 (3,338 bp). Expression of *C9orf72* isoforms is presented in percentage of the total (100%) *C9orf72* expression. t tests were performed between groups, and n.s. indicates no significant differences in the levels of all isoforms. (D) Estimation of the read depth per region in *C9orf72*. Read depth was estimated for exon 1a, intron 1, exon 1b, exon 2, and exon 11 in cerebellum from C9-ALS patient and controls. The total amount of reads per region was counted and corrected for the area size. Each dot or triangle represents a single sample. (E) Ratio of reads between C9-ALS patients and controls in cerebellum. The total amount of reads counted in different intronic and exonic regions from C9-ALS patients was divided by the total amount of reads from the same region of control donors. Data were evaluated using two-way ANOVA with Tukey's multiple comparison: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.

of C9-ALS patients, the coverage ratio between intronic and exonic regions was increased (Figure S1). Thus, although exonic regions were expressed 2-fold lower in C9-ALS patients, this was not the case for introns 1–4, suggesting that intronic *C9orf72* reads are relatively overexpressed in C9-ALS patients. Our data confirm previous findings that the higher amount of intronic sequences in the *C9orf72* mRNA could be due to aberrant splicing.^{36,37}

Design of miRNAs Targeting Conserved *C9orf72* Regions

We selected the well-conserved exon 2 and exon 11 as target sites for a total silencing approach. Due to the poor coverage of intron 1, we selected regions that have been successfully targeted before by ASOs.¹³ For the antisense strand, a region that has been identified before by PCR was selected.²¹ We designed miC expression constructs miC1–miC11 and miC22–miC31 in intron 1 to target only the sense intronic transcripts (Figure 2A). miC32–miC50 was designed in exon 2 and exon 11 to target all sense *C9orf72* transcripts. miC12*–miC22* was designed on the antisense strand to target only the antisense transcripts and is indicated with asterisks. The miC sequences were embedded in the pri-miR-101 and pri-miR-451 scaffold because of previous findings by us that both scaffolds produce high amount of active guide strands.²⁹ The pri-miC-101 and pri-miC-451 structures were predicted to produce mature miC lengths of 21

and 22 nt, respectively (Figure 2B). The miC constructs were expressed by the synthetic cytomegalovirus (CMV) early enhancer and chicken β -actin (CAG) promoter (Figure 2C). This promoter is known to drive stable and high expression of a transgene and is highly active in the CNS.³⁸

In Vitro Testing of miC-101 and miC-451 Constructs on Reporter Systems

To test the efficacy of the miC candidates, we designed Luc reporters bearing complementary *C9orf72* target regions fused to the renilla luciferase (RL) gene (Figure 2D). As targets, intron 1, exon 2, exon 11, and the antisense strand sequences were used. Independently from RL, firefly luciferase (FL) was expressed from the reporter vector to correct for transfection efficiency.

We first performed a prescreening for all the miC expression constructs by co-transfection with the corresponding Luc reporters in a 1:1 ratio. Of the miC variants designed to target the sense intronic transcripts, miC2_101 and miC4_101 showed a moderate knockdown (~50%) and miC31_101 showed a strong knockdown (~80%) (Figure 3A). These were selected for further optimization. Among candidates predicted to target total *C9orf72*, miC32_101, miC33_101, miC38_451, miC39_451, miC40_451, and miC43_451




Figure 2. Design of Artificial miC Expression Constructs Targeting Sense and Antisense *C9orf72*

(A) Schematic representation of the human *C9orf72* gene consisting of 12 exons, including the alternatively spliced exons 1a and 1b and the intronic G₄C₂ repeat. The positions of the miC target sites are indicated with numbers. Numbers in green show positions of ASOs described by Lagier-Tourenne et al.¹⁷ In gray are the sense-targeting miC candidates embedded in the miR-101 scaffold, in blue are sense-targeting miC candidates embedded in the miR-451 scaffold, and in red are the antisense-targeting miC candidates embedded in the miR-451 scaffold. (B) Schematic of the miC-101 and miC-451 secondary structures. The scaffolds were selected from miRBase database (www.mirbase.org). The guide strand was replaced by the mature miC sequence, and the passenger strand was corrected in order to preserve pri-miC scaffolding. miR-101 can be processed into active guide strands (red) and in some cases passenger strands (gray). miR-451 produces only guide strands. (C) Schematic of the pri-miC-451 and pri-miC-101 constructs consisting of the CAG promoter, pri-miC sequence, and human growth hormone polyadenylation (hGH polyA) signal. (D) Schematic of the reporter genes. To represent the *C9orf72* sense transcripts, sequences from *C9orf72* intron 1 (int 1a and int 1b), exon 2 (ex2), and exon 11 (ex11) were cloned downstream of the RL gene. In addition, FL was co-expressed from the vector as an internal control. For the antisense reporter (AS), the intronic antisense sequence was cloned.

targeting exon 2 showed a strong knockdown of >80% (Figure 3B). Similarly, miC46_101, miC49_451, and miC50_451 targeting exon 11 induced a strong knockdown (>80%) (Figure 3C). Dilution of the selected miC candidates demonstrated that the most effective candidates were miC31_101 against intron 1 (Figure 3E), miC32_101 against exon 2 (Figure 3F), and miC46_101 against exon 11 (Figure 3G).

For the antisense *C9orf72* transcript, miC15_451* and miC21_451* were selected as the most effective candidates with a knockdown efficiency of ~70% (Figure 3D). Both miC15_451* and miC21_451* showed an equal dose-dependent knockdown (Figure 3H).

Our data demonstrate that intron 1 remains a difficult target region, as all miC candidates in the highly structured repeat region between exons 1a and 1b failed to induce a strong knockdown. The most effective miC candidates were downstream of exon 1b or in exonic regions 2 and 11. Yet, if a moderate knockdown of the G₄C₂ repeat would be sufficient for a therapeutic effect, miC2_101 and miC4_101 could still be promising candidates to target the repeat-containing transcripts in C9-ALS patients.

Bidirectional Targeting of *C9orf72* Is Possible by the Introduction of a Second miC Concatenate

The region around the G₄C₂ repeat of *C9orf72* is transcribed in both sense and antisense transcripts, and both strands have been linked to toxicity. Therefore, a therapy simultaneously targeting both strands could potentially add to therapeutic benefit. To investigate the feasibility for this approach using miRNAs, we made concatenated constructs expressing two hairpins predicted to target both transcripts under the control of the CAG-promoter (Figure 4A). The first hairpin from the concatenated hairpin miRNA construct was in a miR-451 scaffold and targets the antisense transcript. The second hairpin was in a miR-101 scaffold against the sense transcripts. The most effective candidates on Luc reporters for intron 1 sense and antisense were selected. The miC15*+31 construct was designed to express miC15_451* and miC31_101, and it was tested on the intron 1 and antisense reporters (Figures 4B and 4C). A silencing of up to 60% was observed on the intron 1 sense and on the antisense reporter. Similarly, miC21*+31 expressing miC21_451* and miC31_101 was made and tested, and up to a 60% knockdown was observed on both reporter constructs (Figures 4D and 4E). Both constructs showed a dose-dependent reduction of the intron 1 sense and




Figure 3. Silencing Efficacy of miC Candidates on Luc Reporters

(A) Knockdown by miC1 to miC11 and miC22 to miC31 targeting intron 1 either between exon 1a and the G₄C₂ repeat or between exon 1b and exon 2. HEK293T cells were co-transfected in a 1:1 ratio with Luc reporters and the different miC variants embedded in miR-101 (gray bars) or miR-451 (blue bars) scaffolds. RL and FL were measured 2 days post-transfection, and RL was normalized to FL expression. Scrambled miRNA (miScr) served as a negative control and was set at 100%. Candidates selected for further testing are underlined. (B and C) Knockdown of exon 2 reporter (B) by miC32 to miC45 and exon 11 reporter (C) by miC46 to miC50. (D) Knockdown of the antisense reporter by miC12_451* to miC21_451*. (E–H) Dose-dependent effects of the selected miC candidates on Luc reporters. HEK293T cells were co-transfected with 10 ng Luc reporters and 1, 5, 10, and 25 ng of the selected miC constructs for intron 1 (E), exon 2 (F), exon 11 (G), and the antisense transcript (H). RL and FL luciferases were measured as described above. Data were analyzed using a multiple-comparison one-way ANOVA to determine statistical significances for cells treated with scrambled and miC. The p values of miC candidates selected for further testing are listed in the graph by asterisks: ****p < 0.0001. Each bar represents the average and SD of 3 independent experiments.

low levels (Figure 5A). For miC candidates in the miR-101 scaffold, total *C9orf72* mRNA was reduced up to 50% by miC32_101, miC33_101, and miC46_101 (Figure 5B). The intronic *C9orf72* transcripts were also decreased by ~25% (Figure 5C). miC2_101 and miC4_101 targeting intron 1 were less effective in lowering total *C9orf72*, but the efficacy on intronic *C9orf72* was comparable to miC candidates targeting total *C9orf72*. Thus, both candidates may

be targeting the repeat-containing transcripts without significantly changing the total *C9orf72* expression. miC31_101 targeting intron 1 showed the best efficacy for the intronic *C9orf72* (40%); but, despite its intronic localization, the total *C9orf72* RNA levels were also reduced by ~40% (Figures 5B and 5C). Reduction of *C9orf72* was also observed by the selected miC candidates in the miR-451 scaffold, but their efficacy was slightly lower. Altogether, we demonstrated the reduction of endogenous levels of *C9orf72* in HEK293T cells, confirming that the miC candidates are functional in cells.

Endogenous Knockdown of *C9orf72* Expression in HEK293T Cells by miC Variants

We next investigated whether the selected miC candidates reduce the endogenous levels of *C9orf72* in HEK293T cells. Cells were transfected with the selected miC candidates, and endogenous levels of *C9orf72* mRNA were determined 2 days post-transfection by qRT-PCR. As HEK293T cells lack the G₄C₂ expansion linked to the *C9orf72* pathology, we first determined the expression of total *C9orf72* and intronic *C9orf72* mRNA. We found good expression of total *C9orf72*, while the intronic *C9orf72* was detectable but at very

low levels (Figure 5A). For miC candidates in the miR-101 scaffold, total *C9orf72* mRNA was reduced up to 50% by miC32_101, miC33_101, and miC46_101 (Figure 5B). The intronic *C9orf72* transcripts were also decreased by ~25% (Figure 5C). miC2_101 and miC4_101 targeting intron 1 were less effective in lowering total *C9orf72*, but the efficacy on intronic *C9orf72* was comparable to miC candidates targeting total *C9orf72*. Thus, both candidates may be targeting the repeat-containing transcripts without significantly changing the total *C9orf72* expression. miC31_101 targeting intron 1 showed the best efficacy for the intronic *C9orf72* (40%); but, despite its intronic localization, the total *C9orf72* RNA levels were also reduced by ~40% (Figures 5B and 5C). Reduction of *C9orf72* was also observed by the selected miC candidates in the miR-451 scaffold, but their efficacy was slightly lower. Altogether, we demonstrated the reduction of endogenous levels of *C9orf72* in HEK293T cells, confirming that the miC candidates are functional in cells.

Different Processing Pattern from the miR-101 and miR-451 Scaffolds

To assess the processing of the miC candidates, we analyzed the mature miC lengths and sequence composition of the guide and passenger strands by NGS for small transcriptome analysis (Figures 5D and 5E). NGS was performed on small RNAs isolated from HEK293T cells that were transfected with the selected miC




Figure 4. Efficacy of Double-Hairpin Constructs for Bidirectional Knockdown

(A) Schematic of the concatenated pri-miC-451 and pri-miC-101 construct consisting of the CAG promoter, two pri-miC sequences in miR-451 and miR-101 scaffolds, and human growth hormone polyadenylation (hGH polyA) signal. (B) Optimization of miC15*+31 on Luc-intron 1b reporter. HEK293T cells were co-transfected with 10 ng Luc-intron 1b reporter and 1, 5, 10, or 25 ng miC15*+31 construct designed to simultaneously target both sense and antisense *C9orf72* transcripts. miC31_101 (targeting only sense) was used as a positive control and miC15_451* served as a negative control. RL and FL were measured as described in Figure 3. (C) Optimization of miC15*+31 on the antisense reporter. miC15_451 was tested as a positive control for the antisense reporter and miC31_101 as a negative control. (D) Knockdown of Luc-intron 1b reporter by miC21*+31 with miC31_101 as a positive control and miC21_451* as a negative control. (E) Dose-dependent knockdown of the antisense reporter by miC21*+31. miC21_451* served as a positive control and miC31_101 as a negative control. Error bars represent the average and SD of 2 independent experiments.

constructs. For each sample, we obtained between 15 and 30 million small RNA reads that were subsequently adaptor trimmed and aligned against the corresponding reference sequence. All reads shorter than 10 nt, longer than 45 nt, or represented less than 10 times were excluded from the analysis.

miR-101 is processed into a miRNA duplex, first by Drosha cleavage and then by Dicer cleavage at the hairpin structure (Figure S2). The miRNA duplex is then separated, and the guide strand is usually incorporated into the RNA-induced silencing complex (RISC), while in most cases the passenger strand is degraded.^{39–41} The miC-101 candidates were processed into a 20- to 23-nt-long mature miRNA (Figure 5D). The most frequently found length of guide strands was 22 nt, which is 1 nt longer than the cleavage pattern predicted by miRBase (<http://www.mirbase.org/>) (Table S1). The length of the passenger strands ranged between 19 and 23 nt. In most cases, Drosha cleavage sites of the mature miC-101 at the 3' end of the pre-miC-101 candidates were precise and consistent with the prediction from miRBase, except for miC33_101 and miC49_101. Following cleavage by Drosha, the hairpin of the pre-miC_101 was being cleaved by Dicer. Dicer cleavage in the hairpin generated more variability for almost all the miC variants. Processing of miC2_101, miC4_101, miC32_101, and miC33_101 yielded a high frequency of guide strands with very low percentages of the passenger strand. miC46_101 processing yielded more passenger strand, while miC49_101 and miC50_101 produced a relatively equal amount of guide and passenger strands.

The processing of the miC-451 candidates did not produce passenger strands but often generated longer guide strands than the predicted 22 nt obtained from miRBase (Figure 5E; Table S2).

Drosha cleavage sites at the 5' end of the mature miC-451 were precise, but the trimming of the 3' ends of the mature miC-451 by poly(a)-specific ribonuclease (PARN) were different for most candidates, leading to a variety of mature lengths. miC39_451, miC43_451, and miC49_451 processing generated most often mature lengths between 21 and 26 nt long, and processing of miC38_451 and miC50_451 often resulted in mature lengths longer than 27 nt.

Overall, we demonstrated that expressing different *C9orf72* target sequences from the miR-101 scaffold yields a differential processing of mature guide and passenger strands. Using the miC-451, no passenger strands were detected, but this scaffold often generated longer mature guide strands.

miC-101 and miC-451 Are Active in the Nucleus

pre-miRNAs are transported from the nucleus to the cytoplasm for further processing and incorporation into the RISC.^{39–41} However, because *C9orf72*-related ALS and FTD are characterized by accumulation of the G₄C₂-containing transcripts in the nucleus, mature miC should be active in the cell nucleus to achieve therapeutic effect. Based on the efficacy *in vitro*, we selected miC2_101 and miC4_101 as the most promising candidates to target only the intronic transcripts. Similarly, miC32_101, miC46_101, miC49_451, and miC50_451 were selected for a total silencing approach, based on their strong silencing efficacy *in vitro*. HEK293T cells were transfected with the different miC candidates; nuclear and cytoplasmic fractions were separated; and expressions of the mature miC2,

miC4, miC32, miC46, miC49, and miC50 in nucleus and cytoplasm were evaluated.

We detected mature miC in both nucleus and cytoplasmic fractions for all miC candidates, but the expression levels in nucleus were consistently ~5-fold lower compared to cytoplasm (Figures 5F and 5G). Next, we evaluated the silencing efficacy of the miC candidates in nucleus and cytoplasm by measuring the endogenous levels of total *C9orf72* mRNA. miC32_101, miC46_101, and miC49_451 caused a reduction of total *C9orf72* mRNA in both nucleus and cytoplasm (Figures 5H and 5I). However, the silencing efficacy in the nucleus was lower compared to cytoplasm, consistent with the lower miC levels detected in the nucleus. As expected, miC2_101 and miC4_101, which target the intronic *C9orf72* transcripts, had limited to no effect on the total *C9orf72* expression. Thus, our data suggest that the mature miC-101 and miC-451 can both shuttle from the cytoplasm to the cell nucleus and can actively induce knockdown. Reduction of *C9orf72* was observed in both the nucleus and cytoplasm, suggesting that both scaffolds can be used for further development into gene therapy for ALS and FTD.

Reduction of Nuclear RNA Foci by miC Variants in (G₄C₂)₄₄-Expressing Cells

A hallmark of the RNA-mediated toxicity in ALS and/or FTD is the formation of toxic RNA foci by the repeat-containing transcripts. We generated a cell model that develops nuclear RNA foci using methods similar to those described previously.^{42,43} We expressed constructs consisting of (G₄C₂)₄₄ or (G₄C₂)₃, including 150-nt 5'- and 50-nt 3'-flanking regions linked to *C9orf72* exon 2 in HEK293T cells. Nuclear RNA foci were visualized by fluorescence *in situ* hybridization (FISH) using a TYE563-(C₄G₂)₃ locked nucleic acid (LNA) probe. However, we were not able to detect DPR proteins in these cells, as the assay is technically challenging. Using a GFP construct, the transfection efficiency was determined to be ~95%–100% (data not shown). We observed sense RNA foci at 2 days post-transfection in ~40% of (G₄C₂)₄₄ cells (Figure 6A), but antisense RNA foci were not detected (data not shown). RNA foci were primarily present in the nucleus. Control cells expressing a shorter (G₄C₂)₃ repeat did not accumulate RNA foci. To evaluate whether the foci were RNA specific, transfected cells were treated with RNase or DNase (Figure 6A). Almost all observed foci were degraded by RNase, but not DNase, confirming that the observed foci were primarily composed of RNA.

miC4_101 and miC32_101 were evaluated for efficacy on RNA foci formation by co-transfection. Both miC candidates significantly decreased the percentage of (G₄C₂)₄₄ foci-positive cells by ~50% after 24 h (Figures 6B and 6C). miScr served as the control and did not reduce the amount of foci in the cells. This confirms that our miC candidates were functional in reducing RNA foci in the cell nucleus.

Reduction of Endogenous *C9orf72* in Cells by AAV5-miC


To further investigate the silencing of *C9orf72* in the context of a gene therapy for ALS and FTD, we selected miC32_101 as the best

candidate to target total *C9orf72*, based on the strong efficacy and low frequency of passenger strand formation. miC46_101 was selected as the most effective candidate based on silencing efficacy, but its high amount of passenger strand could make it less suitable to treat patients. Both candidates were incorporated into AAV5. Increasing doses of AAV5-miC32_101 and AAV5-miC46_101 were used to transduce HEK293T cells and iPSC-derived frontal brain-like neurons from an FTD patient. Expressions of the mature miC32 and miC46 were verified using TaqMan. Cells transduced with AAV5-GFP served as a control for the transduction efficiency. At 3 days post-transduction, AAV5-GFP transduced ~80% of HEK293T cells (Figure 7A). The mature guide strand expressions of miC32 and miC46 were expressed in a dose-dependent manner and resulted in a dose-dependent reduction of total *C9orf72* expression at a maximum of ~40%–50% (Figures 7B and 7C). The levels of mature miC32_101 and miC46_101 produced in transduced cells correlated well with *C9orf72* silencing (Figures 7D and 7E). Similarly, miC expression and up to 50% lowering of C9ORF72 was observed in transduced frontal brain-like neurons (Figures 7F and 7G). Hence, these data provide a strong rationale for further proof-of-concept studies in animal models of *C9orf72*-ALS, leading toward a miRNA-based gene therapy to treat ALS and FTD.

Our results indicate that miRNAs could be used as therapeutics to reduce the gain of toxicity caused by the G₄C₂ expanded repeat of *C9orf72*. We demonstrated the feasibility of different targeting approaches by miC to silence the sense, antisense, or both transcripts of *C9orf72*. In addition, the processing of miC in the miR-101 and miR-451 was demonstrated, and both scaffolds produced mature miC that was functional in the cell nucleus and cytoplasm. Silencing of *C9orf72* by AAV5-miC was demonstrated in patient-derived frontal brain-like neurons, providing promising results for further development of a miRNA-based gene therapy for ALS and FTD.

DISCUSSION

A G₄C₂ repeat expansion in intron 1 of *C9orf72* is the most frequent cause of ALS and FTD, leading to the accumulation of sense and antisense RNA foci in the cell nucleus and DPR proteins in the cytoplasm. Here we report on the design and characterization of an AAV-delivered miRNA-based approach to target *C9orf72* transcripts, with potentially a long-lived therapeutic effect following a single administration. We analyzed RNA-seq data from C9-ALS patients to investigate *C9orf72* expression and sequence conservation to predict potential target regions for a miRNA-based targeting approach. We observed reduced levels of *C9orf72* in cortex and cerebellum from C9-ALS patients. This finding is consistent with other studies where the significant reduction of *C9orf72* was also reported in brain and spinal cord tissues and in iPSC-derived neurons from patients.^{2,37,44–46} Some studies reported that the V2 variant from *C9orf72* was the most affected transcript variant.^{44,47} We did not find evidence that the reduction seen in patients was variant specific. Reduced transcription of *C9orf72* in ALS patients could be a result of epigenetic silencing due to CpG hypermethylation of the G₄C₂ repeat, and this raises the question whether haploinsufficiency also



(legend on next page)




Figure 6. miC Variants Inhibit RNA Foci Formation in $(G_4C_2)_{44}$ -Expressing Cells

(A) RNA foci detected in HEK293T cells expressing $(G_4C_2)_{44}$. Cells were transfected with 250 ng $(G_4C_2)_{44}$ and $(G_4C_2)_3$ plasmid and fixed 2 days post-transfection after treatment with DNase or RNase. RNA FISH was performed using a TYE563-(CCCCG)₃ LNA probe (red), and nuclei were stained with DAPI (blue). Nuclear foci were resistant to DNase but degraded by RNase indicating RNA foci. (B) Reduction of RNA foci by miC4_101 and miC32_101. Cells were co-transfected with 250 ng $(G_4C_2)_{44}$ and 100 ng miC4_101, miC32_101, or miScr plasmid. Cells were fixed 2 days post-transfection, and RNA FISH was performed as described in (A). (C) Quantification of RNA foci in miC4_101- and miC32_101-transfected cells. A series of five images was made using 10 \times magnification to quantify the number of cells containing nuclear foci using ImageJ (mean \pm SD, one-way ANOVA, multiple-comparison test, **** p < 0.001).

contributes to the pathology of the disease.⁴⁷ However, a significant body of evidence also supports a G_4C_2 -mediated toxicity.^{46–49}

To identify potential miC target sites, we investigated the sequence conservation of *C9orf72*. Whereas exonic regions from exon 2 to exon 11 were completely covered, intronic regions were poorly represented, and not much can be concluded about the conservation of intron 1-containing transcripts in patients. Despite the low coverage, read alignment for intronic regions was found in both patients and

controls. Interestingly, the coverage of the introns 1–4 was relatively higher in C9-ALS patients than in controls, supporting findings that the impairment of full-length *C9orf72* transcription in patients could be a result of the accumulation of aberrant or unspliced *C9orf72* transcripts.^{36,37} Directly targeting intron 1 is a challenging therapeutic strategy, due to the low expression and difficulty to detect intron 1-containing transcripts, as well as its high GC content. Moreover, GC-rich regions are common in the genome, and therapeutics targeting such regions should be carefully investigated for off-target effects.

Figure 5. Lowering of Endogenous *C9orf72* mRNA

(A) Total and sense intronic *C9orf72* expression in HEK293T cells. RNA was isolated, and qRT-PCR was performed for total and sense intronic *C9orf72* transcripts. mRNA input levels were normalized to GAPDH and set relative to total *C9orf72*. (B and C) Endogenous knockdown of total *C9orf72* (B) and sense intronic *C9orf72* (C) by the selected miC candidates. qRT-PCR for total and sense *C9orf72* was performed on RNA from HEK293T cells that were transfected with 250 ng of different miC plasmids. mRNA input levels were normalized to GAPDH mRNA. miScr served as a negative control and was set at 100%. (D) Processing of miC-101 candidates. HEK293T cells were transfected with 250 ng of the constructs. At 48 h post-transfection, RNA was isolated, and small RNA NGS was performed to determine the length and ratio of guide and passenger strands. (E) Processing of miC-451 candidates, performed as described in (D). (F) Cytoplasmic and nuclear expressions of miC candidates in the miR_101 scaffold. RNA was isolated from the cytoplasm and nucleus of HEK293T cells transfected with 250 ng miC plasmid. miC levels were measured by small RNA TaqMan, and mRNA input levels were normalized to u6 small nuclear RNA and set relative to untreated (BL) cells. (G) Expression of miC candidates in miR-451 in cytoplasm and nucleus, performed as described in (F). (H) Reduction of total *C9orf72* by miC-101 in cytoplasm and nucleus. qRT-PCR for total *C9orf72* was performed on cytoplasmic and nuclear fractions of transfected cells. mRNA input levels were corrected for GAPDH and BL was set at 100%. (I) Total *C9orf72* reduction in the nucleus and cytoplasm by miC-451, performed as described in (H). Data were analyzed using a multiple-comparison one-way ANOVA to determine statistical significances for cells treated with scrambled or BL and miC. The p values are listed in the graph by asterisks: * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. Each graph represents the mean values with SD of 2 independent experiments.




Figure 7. Silencing of Endogenous *C9orf72* by AAV5-miC

(A) Transduction efficiency by AAV5 in HEK293T cells. Cells were transduced with 1e12 genomic copies (gc) AAV5-GFP and visualized 3 days post-transduction. (B) Levels of mature miC32_101 and miC46_101 guide strands in transduced cells. Cells were transduced with 2e10, 2e11, and 2e12 gc AAV5-miC32_101 and AAV5-miC46_101. RNA was isolated 3 days post-transduction to determine expression of the mature miC32_101 and miC46_101 by TaqMan. MicroRNA input levels were normalized to U6 small nuclear RNA and set relative to PBS-treated cells. (C) Silencing of *C9orf72* in transduced HEK293T cells, performed as described in (B). Total *C9orf72* was determined by qRT-PCR. mRNA input was normalized to GAPDH and set relative to PBS-treated cells. (D) Correlation of miC32_101 expression levels and *C9orf72* knockdown in cells upon transduction with AAV5-miC32_101. Pearson correlation ($r = -0.925$). (E) Correlation of miC46_101 expression levels and *C9orf72* knockdown in cells transduced with AAV5-miC46_101 ($r = -0.808$). (F) Levels of mature miC32_101 and miC46_101 guide strands in transduced iPSC-derived frontal brain-like neurons from an FTD patient. Cells were transduced with 2e11 and 2e12 gc AAV5-miC32_101 and AAV5-miC46_101. RNA was isolated 7 days post-transduction to determine expression of the mature miC32_101 and miC46_101 by TaqMan. MicroRNA input levels were normalized to U6 small nuclear RNA and set relative to AAV5-GFP-treated cells. (G) Reduction of *C9orf72* in iPSC-derived frontal brain-like neurons from an FTD patient, performed as described in (F). Total *C9orf72* levels were determined by qRT-PCR. mRNA input was normalized to GAPDH and set relative to cells treated with AAV5-GFP. Data were evaluated using two-way ANOVA, multiple-comparison test: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$. Each graph represents the mean values with SD of 2 independent experiments.

The coverage of the antisense transcript was very poor, and limited coverage was found only in the 5' UTR of *C9orf72*. In contrast, exonic regions had complete coverage and, therefore, are much easier to target.

We designed miC candidates with intron 1-binding sites to target only the sense intronic transcripts and candidates binding within exon 2 and exon 11 to target all sense transcripts. miC candidates were also designed to specifically target the antisense transcripts of *C9orf72*.

In line with our difficulties to detect the repeat-containing transcripts with RNA-seq, the repeat region could also be less accessible for the mature miC due to its highly structured nature. Only two miC candidates targeting the G₄C₂ region showed a moderate knockdown of the intron 1 reporter. It is also possible that the high GC content of the mature miC itself interferes with strand loading and target recognition. miC candidates further downstream of the G₄C₂ repeat in intron 1 or in exon 2 and exon 11 showed a much stronger knockdown of the Luc reporters, and two miC candidates were also effective on the antisense reporter.

One challenge for our miC approach is the simultaneous targeting of sense and antisense transcripts. To test the feasibility of such an approach, we designed a construct that expresses two miC molecules in a concatenated fashion against both sense and antisense transcripts. Silencing of both the intron 1 reporter and the antisense reporter constructs was achieved, demonstrating the feasibility for a bidirectional silencing of *C9orf72* by miC. Combining two or more miRNA hairpins in a single construct has been successfully performed previously, and one study showed increased silencing efficacy by miRNAs in a polycistron setting.^{50,51} Thus, expressing different miC in a concatenated fashion could be promising to target both sense and antisense transcripts of *C9orf72*.

In this study, we used two differentially processed miRNA scaffolds, miR-101 and miR-451. The pre-miR-101 follows the canonical processing pathway, as the further downstream processing in the cytoplasm involved Dicer cleavage of the hairpin to generate 5' arm strands and 3' arm strands. The 5' arm strand, which becomes the passenger strand, is usually degraded, though both strands could be incorporated into the RISC and loaded onto Argonaute (Ago), producing active guide and passenger strands that cleave the complementary mRNA (Figure S2). The pre-miR-451 follows the non-canonical pathway as it escapes Dicer cleavage, producing only a 5' arm that is subsequently cleaved by Ago and trimmed by PARN into 22- to 24-nt guide strands that are incorporated into the RISC (Figure S3). However, trimming of miR-451 can result in functional guide strands that are longer than the mature length.^{29,52} Thus, both miR-101 and miR-451 are promising, but simultaneous guide and passenger strand expressions or mature miC much longer than the predicted length may increase the chance of hitting non-target genes due to miRNA-like effects. Hence, it is important to determine the processing of miC candidates in both scaffolds and assess target similarity with other genes to minimize off-target effects.

The processing of the miC candidates was determined by NGS analysis. We confirmed a differential processing of the various miC-101 candidates, resulting in different ratios of guide and passenger strands. miC2_101, miC4_101, miC32_101, and miC33_101 produced low amounts of passenger strand and are predicted to have few off-target effects. miC46_101, miC49_101, and miC50_101 may have an increased risk for off-target effects due to the high amount of passenger strands. The finding that the miC-101 candidates were differently processed, even in the same miRNA scaffold, supports previous obser-

vations that not only the pri-miRNA scaffold but also the miRNA-sequence are critical for choosing which sequences of the duplex enter the RISC.^{29,53–56} This strand selection has been extensively studied, and it seems to be also dependent on the difference in stability of the miRNA duplex at the 5' ends of each strand.^{29,54–59} miC-451 candidates did not show any passenger strand activity. However, miC38_451 and miC50_451 produced mature guide strands longer than 27 nt, and they could also have increased risk for off-target effects. The different miC-processing pattern suggests that selection of *C9orf72*-silencing candidates should be based on a balanced assessment of silencing efficacy and NGS processing data.

The efficacy of the best miC candidates was further confirmed by their ability to reduce endogenously expressed *C9orf72* mRNA. We found up to ~50% reduction of total *C9orf72* mRNA and ~25% reduction of intronic transcripts by miC candidates targeting exon 2 or exon 11. The silencing efficacy of miC-451 was slightly lower compared to miC-101, consistent with the lower levels of mature miC-451 detected by NGS. Two miC candidates targeting the repeat region had limited effect on the total *C9orf72* mRNA expression, but the reduction of the intronic transcripts was comparable with candidates targeting the total *C9orf72* mRNA. Thus, a total silencing approach and a mutant-specific approach can both result in lowering G₄C₂ repeat-containing *C9orf72* transcripts.

Another challenge for therapeutic miC is the nuclear localization of the toxic transcripts. Thus, recognition of the transcripts by the miC candidates within the nucleus is required, whereas the mature miC is produced in the cytoplasm. Nuclear RNA foci have been found in different neuronal cells of patients, including spinal motor neurons, cerebellar Purkinje cells, cerebellar granule cells, hippocampal neurons, and pyramidal cells in the motor cortex.¹⁷ We report that the mature miC-101 and miC-451 candidates are detected in both nucleus and cytoplasm, and they lower *C9orf72* mRNA in both cellular structures. There is increasing evidence that miRNA-RISC components, such as Ago and Dicer, are present in the cell nucleus and retain their catalytic activity in the nucleus.^{60,61} The current assumption is that miRNA-AGO complexes that are formed in the cytoplasm can travel back into the nucleus.⁶¹ Indeed, we detected a reduction of nuclear RNA foci after treatment with miC candidates targeting intronic *C9orf72* or total *C9orf72* transcripts.

A critical factor determining the success of a gene therapy is the selected delivery system to the target cells or tissues. It is likely that a widespread transduction of neurons in the whole brain and spinal cord, including glia cells, will be required to achieve disease-modifying therapeutic effect in ALS and/or FTD patients. AAV vectors exhibit important advantages, including high transgene expression, long-term stability, and positive safety profile due to the non-pathogenic nature of the wild-type form.⁶² We demonstrated high expression of miC levels and up to 50% reduction of total *C9orf72* by AAV5-miC candidates in iPSC-derived frontal brain-like neurons from an FTD patient. It remains questionable how much reduction is required to achieve a rescue effect on the disease phenotype. However, previous

findings using ASOs in an ALS mouse model without a clear clinical phenotype showed between 40%–60% reduction of *C9orf72*, which appears to be sufficient to reduce RNA foci formation by ~50% and DPR proteins by ~80%.¹³

The delivery of RNAi-based AAV treatment strategies in ALS have predominantly been explored in preclinical studies to treat SOD1-ALS and have demonstrated to be promising.^{63–66} AAV9 resulted in the effective transduction of spinal cord and motor neurons, but sufficient widespread distribution in the adult CNS upon systemic injection remains challenging.^{66–68} In children with spinal muscular atrophy type 1, a single intravenous infusion of AAV9 for gene replacement therapy resulted in widespread transduction of neurons within the spinal cord and significant clinical improvement.⁶⁹ However, for an RNAi-based approach in adult ALS and FTD patients, the blood-brain barrier (BBB) could still be a major obstacle for sufficient transduction of the CNS after systemic delivery. We have previously demonstrated strong transduction of the striatum and cortex and lowering of mutant huntingtin protein, in a Huntington's disease minipig model, after direct injection of AAV5 into the striatum.⁷⁰ Furthermore, intrastriatal injections of AAV5 have been shown to distribute via axons through anterograde and/or retrograde transport and resulted in the transduction of different types of neurons, astrocytes, microglia, and oligodendrocytes.^{70,71} Thus, a local delivery to the brain parenchyma is promising in patients with FTD for treatment of the symptoms associated with cortical degeneration. Parenchymal delivery of AAV also resulted in the transduction of motor neurons along the corticospinal tract in non-human primates.⁷² However, it needs to be assessed whether the transduction of motor neurons is sufficient to achieve therapeutic concentrations of AAV. An alternative approach could be intrathecal administration, but further studies in large animals are required to predict the efficacy in the brain and spinal cord. Ultimately, intrathecal administration combined with parenchymal administration to the brain may be required to obtain sufficient transduction of the affected areas in ALS and ALS and/or FTD patients.

In summary, following an RNA sequence analysis of *C9orf72* in ALS patients and controls, we rationally designed miC candidates using the miR-101 and miR-451 scaffolds to target total, intronic, and antisense *C9orf72* transcripts. We demonstrated that specifically targeting the G₄C₂ repeat by miC is possible but challenging. The feasibility of a bidirectional approach was also demonstrated by expressing two miC hairpins targeting the sense and antisense *C9orf72* in a concatenated fashion. The efficacy of the miC candidates was evaluated based on their ability to lower *C9orf72* mRNA, and the processing was determined by NGS. In addition, we also provided evidence that miC can be active in the nucleus by the reduction of nuclear *C9orf72* mRNA and RNA foci.

MATERIALS AND METHODS

RNA-Seq and *C9orf72* Target Sequences

An RNA-seq library published by Prudencio et al.³¹ was downloaded. The data were analyzed by BaseClear B.V. In brief, we downloaded

RNA-seq samples from the Sequence Read Archive (SRA) from NCBI GEO: GSE67196 (<https://www.ncbi.nlm.nih.gov/geo/>).³¹ These samples were individually mapped to the human reference genome (GRCh38.p10) with TopHat version 2.1.1.⁷³ The mapped reads from TopHat are fragments per kilobase of transcript per million mapped reads (FPKM) values. Differential gene and isoform expressions were estimated on their relative abundance by Cufflinks 2.2.1.⁷⁴ With the CummeRbund 2.16 R package, we visualized gene and isoform expressions of *C9orf72*.⁷⁵ The alignment (.bam) and junctions files (.bed) generated by TopHat were used by the Integrative Genomics Viewer (IGV) 2.3.94.⁷⁶

DNA Constructs

To generate the miC vectors, we searched for sequences in intron 1, exon 2, and exon 11 of *C9orf72* that were mostly conserved among human and non-human primates and mouse. The miC sequences were incorporated into the cellular pri-miRNA miR-101-1 or miR-451 scaffold of the human. 200-nt 5'- and 3'-flanking regions were included with EcoRV and BamHI restriction sites, and the mfold program (<http://unafold.rna.albany.edu/?q=mfold>) was used to determine if the miC candidates were folded correctly into their secondary structures. The complete sequences were ordered from GeneArt gene synthesis (Invitrogen). These constructs were subsequently cloned into an expression vector containing the CMV immediate-early enhancer fused to chicken β -actin (CAG) promoter (Invivo, Plymouth Meeting, PA) using the EcoRV and BamHI sites. For generation of the Luc reporters, sequences from *C9orf72* intron 1 (sense and antisense), exon 2, or exon 11 were synthesized at GeneArt gene synthesis and cloned in the 3' UTR of the RL gene of the psiCHECK-2 vector (Promega, Madison, WI). The FL gene was also expressed in this vector and served as an internal control (Figure 2D).

Culture and Transfections of HEK293T Cells

HEK293T cells were maintained in DMEM (Invitrogen) containing 10% fetal calf serum (Greiner, Kremsmünster, Austria), 100 U/mL penicillin, and 100 U/mL streptomycin (Thermo Fisher Scientific, Waltham, MA), at 37°C and 5% CO₂. For all assays, cells were seeded in 24-well plates at a density of 0.1*10⁶ cells per well in DMEM. Transfections in HEK293T cells were performed 1 day post-plating with Lipofectamine 2000 reagent (Invitrogen), according to the manufacturer's instructions.

Culture of iPSC Neurons

FTD (ND42765) iPSCs derived from fibroblasts were ordered from Coriell Biorepository (<https://www.coriell.org/>), and they were cultured on Matrigel (Corning)-coated 6-well plates in mTeSR1 (STEMCELL Technologies). For embryoid body-based neural induction, iPSCs were seeded on AggreWell800 plates and cultured in STEMdiff Neural Induction Medium (STEMCELL Technologies) for 5 days with daily medium changes. Embryoid bodies were harvested and plated on 6-well plates coated with poly-D-lysine (Sigma-Aldrich) and laminin (Sigma-Aldrich) in STEMdiff Neural Induction Medium for 7 days with daily medium changes. Rosettes were selected with rosette selection medium and plated on

poly-D-lysine- and laminin-coated 6-well plates in STEMdiff Neural Induction Medium for 24 h. For differentiation into frontal brain-like neurons, STEMdiff Neural Induction Medium was replaced with STEMdiff Neuron Differentiation Medium (STEMCELL Technologies), and neuroprogenitor cells were differentiated for 5 days. The neuroprogenitor cells were then plated on poly-D-lysine- and laminin-coated plates in STEMdiff Neuron Maturation Medium (STEMCELL Technologies) for 1 week. The mature frontal brain-like neurons were stored in liquid nitrogen in Neuroprogenitor Freezing Medium (STEMCELL Technologies).

Luciferase Assays

HEK293T cells co-transfected with the miC expression constructs and Luc reporters were assayed at 48 h post-transfection in 100 μ L $1\times$ passive lysis buffer (Promega) by gentle rocking for 15 min at room temperature. The cell lysates were centrifuged for 5 min at 4,000 rpm to get rid of cell debris, and 10 μ L supernatant was used to measure FL and RL activities with the Dual-Luciferase Reporter Assay System (Promega). Relative luciferase activity was calculated as the ratio between RL and FL activities.

RNA Isolation

For all RNA isolation, cells were lysed in 200 μ L Tryzol, and RNA isolation was performed using the Direct-zol kit (R2061, Zymo Research), according to the manufacturer's protocol.

qRT-PCR and miRNA TaqMan Assay

To determine *C9orf72* mRNA knockdown, HEK293T cells were transfected with different concentrations of the miC variants. Total RNA was isolated from the cells at 2 days post-transfection. Genomic DNA contamination was removed by DNase treatment using recombinant shrimp DNase (Thermo Fisher Scientific). First-strand complementary DNA was reverse transcribed using random hexamer primers with the Dynamo kit (Finnzymes, Espoo, Finland). Real-time PCR amplification was performed with primers targeting total *C9orf72* (forward 5'-CGGAAAGGAAGAATATGGATGC-3', reverse 5'-CCATTACAGGAATCACTTCTCCA-3', and probe 5'-AGCATTGGAATAATACTCTGACCCTGATCTTC-3') or sense intronic *C9orf72* (forward 5'-ACGCCTGCACAATTCAGCCCA-3', reverse 5'-CAAGTCTGTGTCATCTCGGAGCTG-3', and probe 5'-TGAGGGCAGCAATGCAAGTCCGGTGTG-3').⁷⁷ The assays were performed on ABI 7000 or ABI 7500 (Applied Biosystems, Foster City, CA, USA). The mRNA expression levels were normalized to human GAPDH (forward 5'-GAAGGTGAAGGTCGGAGTC-3', reverse 5'-GAAGATGGTATGGGATTC-3', and probe 5'-CAAGCTTCCCGTTCTCAGCC-3') as an internal control, and the level of gene expression was calculated relative to cells transfected with a scrambled plasmid.

To determine the expression of miC, a Custom TaqMan Small RNA Assay Design Tool (Thermo Fisher Scientific) was used to design miC2 (assay ID CTEPR3R), miC4 (assay ID CTFVKNN), miC32 (assay ID CSGJPRB), miC46 (assay ID CSHSNXJ), miC49 (assay ID CTGZE9K), and miC50 (assay ID CTH49UH). All RT reactions

and TaqMan for small RNAs were performed according to the manufacturer's protocols.

RNA Isolation from Nucleus and Cytoplasm Separation

Nucleus and cytoplasm were isolated 2 days post-transfections. Cells were washed with cold $1\times$ PBS, and 100 μ L cold Nuclei EZ Lysis Buffer was added. Cells were incubated on a shaker on ice for 5 min, and nucleus was collected by centrifugation at $500\times g$ for 5 min. The supernatant contained cytoplasmic components and was stored. The pellets were washed twice in 300 μ L cold Nuclei EZ Lysis Buffer, and the pellets containing nuclei components were stored. 200 μ L Tryzol was added to both cytoplasmic and nuclei lysates, and RNA was isolated as described in the previous section.

NGS and Data Analysis

Small RNA-seq libraries for the Illumina sequencing platform were generated using high-quality total RNA as input and the NEXTflex Small RNA-seq kit (Bioo Scientific, Austin, TX) as described before.²⁹ Briefly, the small RNA species were subjected to ligation with 3' and 5' RNA adapters, first-strand reverse transcription, and PCR amplification. Sample-specific barcodes were introduced in the PCR step. The PCR products were separated on Tris/Borate/EDTA (TBE)-PAGE electrophoresis, and the expected band around 30 bp was recovered for each sample. The resulting sequencing libraries were quantified on a BioAnalyzer (Agilent, Santa Clara, CA). The libraries were multiplexed, clustered, and sequenced on an Illumina HiSeq 2000 (TruSeq version [v.]3 chemistry) with a single-read 36-cycle sequencing protocol and indexing. The sequencing run was analyzed with the Illumina CASAVA pipeline (v.1.8.2), with demultiplexing based on sample-specific barcodes. The raw sequencing data produced were processed, removing the sequence reads that were of too low quality (only "passing filter" reads were selected). In total, between 15 and 35 million reads per sample were generated. NGS small RNA raw datasets were analyzed using the CLC Genomics Workbench 8 (QIAGEN). The obtained reads were adaptor trimmed, which decreased the average read size from ~ 50 to ~ 25 bp. All reads containing ambiguity N symbols, shorter than 10 nt, longer than 45 nt, and represented less than 10 times were discarded. Next, the obtained unique small RNA reads were aligned to the reference sequences of the pre-miC constructs with a maximum of 3-nt mismatches allowed. The percentages of reads based on the total number of reads matching the reference sequence were calculated (Table S1).

Cloning of (G₄C₂)₄₄-Exon2 and (G₄C₂)₃-Exon2 Expression Vectors

To generate (G₄C₂)₄₄ and (G₄C₂)₃ expression vectors, we designed a sequence consisting of the intronic *C9orf72* repeat region. The sequence contained either 44 or 3 repeats of the G₄C₂ hexanucleotide, and 150 nt of 5'- and 50 nt of 3'-flanking regions were added. A restriction site Apal was included at the 3' end to serve as a cloning site. These sequences were synthesized and ordered from GeneArt gene synthesis (Invitrogen). To link the (G₄C₂)₄₄ and (G₄C₂)₃ vectors to exon 2, the *C9orf72* exon 2 sequence was ordered at GeneArt gene

synthesis and cloned in the (G₄C₂)₄₄ and (G₄C₂)₃ vectors using the ApaI site.

RNA Foci FISH

RNA FISH was performed as described previously with some adjustments.⁴² In brief, HEK293T cells were grown on the poly-D-lysine-coated 8-well Nunc Lab-Tek Chamber Slide System at a density of 80,000 cells/well. The cells were transfected on day 2 with 200 ng (G₄C₂)₄₄ or (G₄C₂)₃ plasmid. On day 4, cells were fixed in 4% paraformaldehyde for 20 min, permeabilized in ice-cold methanol for 10 min, and washed 3 times with diethylpyrocarbonate (DEPC)-treated PBS (DEPC-PBS). Optionally, cells were treated for 30 min with 5 mg/mL RNase A (QIAGEN) or 100 U RNase-free DNase (Invitrogen). The cells were incubated for 1 h in hybridization buffer (50% formamide, 10% dextran sulfate, 0.1 mg/mL yeast tRNA, 2× saline-sodium citrate (SSC), and 50 mM sodium phosphate) at 37°C and hybridized overnight with 40 nm TYE563-(C₄G₂)₃ LNA probe in hybridization buffer at 37°C. Cells were then washed once with 40% formamide and 1×SSC for 30 min at 37°C and 3 times with DEPC-PBS at room temperature for 5 min. The slides were mounted with ProLong Gold Antifade Mountant with DAPI (Invitrogen) and visualized using a LEICA DM2500 fluorescence microscope.

To determine the effect of miC4 and miC32 on foci formation, HEK293T cells were co-transfected with 200 ng (G₄C₂)₄₄ and 400 ng miC4, miC32, or miScr plasmid. At 2 days post-transfection, cells were fixed and subjected to FISH as described above. To quantify foci-bearing cells, ten fields were randomly selected under 10× magnification. For each field, the number of foci-positive nuclei and the total number of nuclei were counted using ImageJ software. These counts were used to determine the average percentage of foci-positive cells for each condition.

AAV5 Vector Production and Transductions

AAV5 encoding miC32_101 and miC46_101 was produced by a baculovirus-based AAV production system, as described previously.²⁹ Briefly, the miC cassettes were obtained by digestion with restriction enzymes HindIII and PvuI and cloned in a uniQure transfer plasmid named pVD789 in order to generate an entry plasmid. The presence of the two inverted terminal repeats (ITRs) was confirmed by restriction digestion with SmaI. The ITR-CAG-miC cassettes were inserted into a recombinant baculovirus vector by homologous recombination in *Spodoptera frugiperda* Sf9 cells, and clones were selected and screened by plaque purification and PCR. The recombinant baculovirus containing the ITR-CAG-miC cassettes was further amplified until passage 6 (P6) in Sf+ cells and screened for the best production and stability by PCR and qRT-PCR. To generate AAV5, Sf+ cells were triple infected with three different recombinant baculoviruses expressing the ITRs-CAG-miC, the replicon enzyme, and the capsid protein. The cells were lysed 72 h after the triple infection, and the crude lysate was treated with 50 U/mL Benzonase (Merck, Darmstadt, Germany) for 1 h at 37°C. AAV5 was purified on an AVB Sepharose column (GE Healthcare, Little Chalfont, UK) using an AKTA purification system (GE Healthcare). The final titer concentration was determined by

qRT-PCR with primers amplifying a 95-bp fragment from the CAG promoter region.

For transductions with AAV, HEK293T cells were plated in 24-well plates at 0.1×10^6 cells/well in DMEM and transduced with AAV after 24 h. Mature frontal brain-like neurons were plated at 0.3×10^6 cells/well and transduced with AAV after 1 week. RNA isolation and TaqMan for miC32_101, miC46_101, and total *C9orf72* qRT-PCR were performed as described previously.

Statistical Analysis

Data were analyzed using the one-way ANOVA or Student's *t* test to determine statistical significances between control and treated cells. A two-way ANOVA was used to determine statistical significances among multiple treated groups. The *p* values were either listed or represented by the following number of asterisks: **p* < 0.05, ***p* < 0.01, ****p* < 0.001, and *****p* < 0.0001.

SUPPLEMENTAL INFORMATION

Supplemental Information includes three figures and two tables and can be found with this article online at <https://doi.org/10.1016/j.omtn.2019.01.010>.

AUTHOR CONTRIBUTIONS

Conceptualization, P.K. and R.M.; Investigation, R.M., J.M.L., T.v.d.Z., J.M., and J.S.; Supervision, P.K.; Formal Analysis, R.M., J.M.L., and I.K.; Visualization and Writing – Initial Draft, R.M.; Project Administration and Writing – Review and Editing, P.K., S.J.v.D., M.M.E., and H.P.; Funding Acquisition, P.K.

ACKNOWLEDGMENTS

The authors would like to thank Olivier ter Brake and Eileen Sawyer for reviewing the manuscript.

REFERENCES

1. Renton, A.E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J.R., Schymick, J.C., Laaksovirta, H., van Swieten, J.C., Myllykangas, L., et al.; ITALSGEN Consortium (2011). A hexanucleotide repeat expansion in *C9ORF72* is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 72, 257–268.
2. DeJesus-Hernandez, M., Mackenzie, I.R., Boeve, B.F., Boxer, A.L., Baker, M., Rutherford, N.J., Nicholson, A.M., Finch, N.A., Flynn, H., Adamson, J., et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding region of *C9ORF72* causes chromosome 9p-linked FTD and ALS. *Neuron* 72, 245–256.
3. Mancuso, R., and Navarro, X. (2015). Amyotrophic lateral sclerosis: Current perspectives from basic research to the clinic. *Prog. Neurobiol.* 133, 1–26.
4. Nolan, M., Talbot, K., and Ansoorge, O. (2016). Pathogenesis of FUS-associated ALS and FTD: insights from rodent models. *Acta Neuropathol. Commun.* 4, 99.
5. Heutink, P., Jansen, I.E., and Lynes, E.M. (2014). *C9orf72*; abnormal RNA expression is the key. *Exp. Neurol.* 262 (Pt B), 102–110.
6. Gijssels, I., Van Mossevelde, S., van der Zee, J., Sieben, A., Engelborghs, S., De Bleecker, J., Ivanoiu, A., Deryck, O., Edbauer, D., Zhang, M., et al. (2016). The *C9orf72* repeat size correlates with onset age of disease, DNA methylation and transcriptional downregulation of the promoter. *Mol. Psychiatry* 21, 1112–1124.
7. van Blitterswijk, M., DeJesus-Hernandez, M., and Rademakers, R. (2012). How do *C9ORF72* repeat expansions cause amyotrophic lateral sclerosis and frontotemporal dementia: can we learn from other noncoding repeat expansion disorders? *Curr. Opin. Neurol.* 25, 689–700.

8. Mis, M.S.C., Brajkovic, S., Tafuri, F., Bresolin, N., Comi, G.P., and Corti, S. (2017). Development of Therapeutics for C9ORF72 ALS/FTD-Related Disorders. *Mol. Neurobiol.* 54, 4466–4476.
9. Gendron, T.F., Belzil, V.V., Zhang, Y.J., and Petrucelli, L. (2014). Mechanisms of toxicity in C9FTLD/ALS. *Acta Neuropathol.* 127, 359–376.
10. Ling, S.C., Polymenidou, M., and Cleveland, D.W. (2013). Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. *Neuron* 79, 416–438.
11. Ciura, S., Lattante, S., Le Ber, I., Latouche, M., Tostivint, H., Brice, A., and Kabashi, E. (2013). Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. *Ann. Neurol.* 74, 180–187.
12. Koppers, M., Blokhuis, A.M., Westeneng, H.J., Terpstra, M.L., Zundel, C.A.C., Vieira de Sá, R., Schellevis, R.D., Waite, A.J., Blake, D.J., Veldink, J.H., et al. (2015). C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. *Ann. Neurol.* 78, 426–438.
13. Jiang, J., Zhu, Q., Gendron, T.F., Saberi, S., McAlonis-Downes, M., Seelman, A., Stauffer, J.E., Jafar-Nejad, P., Drenner, K., Schulte, D., et al. (2016). Gain of Toxicity from ALS/FTD-Linked Repeat Expansions in C9ORF72 Is Alleviated by Antisense Oligonucleotides Targeting GGGGCC-Containing RNAs. *Neuron* 90, 535–550.
14. Harms, M.B., Cady, J., Zaidman, C., Cooper, P., Bali, T., Allred, P., Cruchaga, C., Baughn, M., Libby, R.T., Pestronk, A., et al. (2013). Lack of C9ORF72 coding mutations supports a gain of function for repeat expansions in amyotrophic lateral sclerosis. *Neurobiol. Aging* 34, 2234.e13–2234.e19.
15. O'Rourke, J.G., Bogdanik, L., Muhammad, A.K.M.G., Gendron, T.F., Kim, K.J., Austin, A., Cady, J., Liu, E.Y., Zarrow, J., Grant, S., et al. (2015). C9orf72 BAC Transgenic Mice Display Typical Pathologic Features of ALS/FTD. *Neuron* 88, 892–901.
16. Almeida, S., Gascon, E., Tran, H., Chou, H.J., Gendron, T.F., Degroot, S., Tapper, A.R., Sellier, C., Charlet-Berguerand, N., Karydas, A., et al. (2013). Modeling key pathological features of frontotemporal dementia with C9ORF72 repeat expansion in iPSC-derived human neurons. *Acta Neuropathol.* 126, 385–399.
17. Lagier-Tourenne, C., Baughn, M., Rigo, F., Sun, S., Liu, P., Li, H.-R., Jiang, J., Watt, A.T., Chun, S., Katz, M., et al. (2013). Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. *Proc. Natl. Acad. Sci. USA* 110, E4530–E4539.
18. Gendron, T.F., Bieniek, K.F., Zhang, Y.J., Jansen-West, K., Ash, P.E.A., Caulfield, T., Daugherty, L., Dunmore, J.H., Castanedes-Casey, M., Chew, J., et al. (2013). Antisense transcripts of the expanded C9ORF72 hexanucleotide repeat form nuclear RNA foci and undergo repeat-associated non-ATG translation in c9FTD/ALS. *Acta Neuropathol.* 126, 829–844.
19. Peters, O.M., Cabrera, G.T., Tran, H., Gendron, T.F., McKeon, J.E., Metterville, J., Weiss, A., Wightman, N., Salameh, J., Kim, J., et al. (2015). Human C9ORF72 Hexanucleotide Expansion Reproduces RNA Foci and Dipeptide Repeat Proteins but Not Neurodegeneration in BAC Transgenic Mice. *Neuron* 88, 902–909.
20. Ash, P.E.A., Bieniek, K.F., Gendron, T.F., Caulfield, T., Lin, W.L., DeJesus-Hernandez, M., van Blitterswijk, M.M., Jansen-West, K., Paul, J.W., 3rd, Rademakers, R., et al. (2013). Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. *Neuron* 77, 639–646.
21. Zu, T., Liu, Y., Bañez-Coronel, M., Reid, T., Pletnikova, O., Lewis, J., Miller, T.M., Harms, M.B., Falchook, A.E., Subramony, S.H., et al. (2013). RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. *Proc. Natl. Acad. Sci. USA* 110, E4968–E4977.
22. Hu, J., Liu, J., Li, L., Gagnon, K.T., and Corey, D.R. (2015). Engineering Duplex RNAs for Challenging Targets: Recognition of GGGGCC/CCCCGG Repeats at the ALS/FTD C9orf72 Locus. *Chem. Biol.* 22, 1505–1511.
23. Nordin, A., Akimoto, C., Wuolikainen, A., Alstermark, H., Forsberg, K., Baumann, P., Pinto, S., de Carvalho, M., Hübers, A., Nordin, F., et al. (2017). Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study. *Amyotroph. Lateral Scler. Frontotemporal Degener.* 18, 256–264.
24. Hu, J., Rigo, F., Prakash, T.P., and Corey, D.R. (2017). Recognition of c9orf72 Mutant RNA by Single-Stranded Silencing RNAs. *Nucleic Acid Ther.* 27, 87–94.
25. Gendron, T.F., Chew, J., Stankowski, J.N., Hayes, L.R., Zhang, Y.J., Prudencio, M., Carlomagno, Y., Daugherty, L.M., Jansen-West, K., Perkerson, E.A., et al. (2017). Poly(GP) proteins are a useful pharmacodynamic marker for C9ORF72-associated amyotrophic lateral sclerosis. *Sci. Transl. Med.* 9, eaai7866.
26. Drouet, V., Perrin, V., Hassig, R., Dufour, N., Auregan, G., Alves, S., Bonvento, G., Brouillet, E., Luthi-Carter, R., Hantraye, P., and Déglon, N. (2009). Sustained effects of nonallele-specific Huntingtin silencing. *Ann. Neurol.* 65, 276–285.
27. Stanek, L.M., Sardi, S.P., Mastis, B., Richards, A.R., Treleaven, C.M., Taksir, T., Misra, K., Cheng, S.H., and Shihabuddin, L.S. (2014). Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington's disease. *Hum. Gene Ther.* 25, 461–474.
28. Boudreau, R.L., Rodriguez-Lebrón, E., and Davidson, B.L. (2011). RNAi medicine for the brain: progresses and challenges. *Hum. Mol. Genet.* 20 (R1), R21–R27.
29. Miniarikova, J., Zanella, I., Huseinovic, A., van der Zon, T., Hanemaaijer, E., Martier, R., Koornneef, A., Southwell, A.L., Hayden, M.R., van Deventer, S.J., et al. (2016). Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease. *Mol. Ther. Nucleic Acids* 5, e297.
30. Snøve, O., Jr., and Rossi, J.J. (2006). Toxicity in mice expressing short hairpin RNAs gives new insight into RNAi. *Genome Biol.* 7, 231.
31. Prudencio, M., Belzil, V.V., Batra, R., Ross, C.A., Gendron, T.F., Pregent, L.J., Murray, M.E., Overstreet, K.K., Piazza-Johnston, A.E., Desaro, P., et al. (2015). Distinct brain transcriptome profiles in C9orf72-associated and sporadic ALS. *Nat. Neurosci.* 18, 1175–1182.
32. Lee, Y., Kim, M., Han, J., Yeom, K.-H., Lee, S., Baek, S.H., and Kim, V.N. (2004). MicroRNA genes are transcribed by RNA polymerase II. *EMBO J.* 23, 4051–4060.
33. Gregory, R.I., Yan, K.P., Amuthan, G., Chendrimada, T., Doratotaj, B., Cooch, N., and Shiekhattar, R. (2004). The Microprocessor complex mediates the genesis of microRNAs. *Nature* 432, 235–240.
34. Han, J., Lee, Y., Yeom, K.H., Kim, Y.K., Jin, H., and Kim, V.N. (2004). The Drosha-DGCR8 complex in primary microRNA processing. *Genes Dev.* 18, 3016–3027.
35. Auyeung, V.C., Ulitsky, I., McGeary, S.E., and Bartel, D.P. (2013). Beyond secondary structure: primary-sequence determinants license pri-miRNA hairpins for processing. *Cell* 152, 844–858.
36. Niblock, M., Smith, B.N., Lee, Y.-B., Sardone, V., Topp, S., Troakes, C., Al-Sarraj, S., Leblond, C.S., Dion, P.A., Rouleau, G.A., et al. (2016). Retention of hexanucleotide repeat-containing intron in C9orf72 mRNA: implications for the pathogenesis of ALS/FTD. *Acta Neuropathol. Commun.* 4, 18.
37. Haeusler, A.R., Donnelly, C.J., Periz, G., Simko, E.A.J., Shaw, P.G., Kim, M.S., Maragakis, N.J., Troncoso, J.C., Pandey, A., Sattler, R., et al. (2014). C9orf72 nucleotide repeat structures initiate molecular cascades of disease. *Nature* 507, 195–200.
38. Klein, R.L., Hamby, M.E., Gong, Y., Hirko, A.C., Wang, S., Hughes, J.A., King, M.A., and Meyer, E.M. (2002). Dose and promoter effects of adeno-associated viral vector for green fluorescent protein expression in the rat brain. *Exp. Neurol.* 176, 66–74.
39. Grimm, D., Streetz, K.L., Jopling, C.L., Storm, T.A., Pandey, K., Davis, C.R., Marion, P., Salazar, F., and Kay, M.A. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. *Nature* 441, 537–541.
40. McBride, J.L., Boudreau, R.L., Harper, S.Q., Staber, P.D., Monteys, A.M., Martins, I., Gilmore, B.L., Burstein, H., Peluso, R.W., Polisky, B., et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. *Proc. Natl. Acad. Sci. USA* 105, 5868–5873.
41. Cifuentes, D., Xue, H., Taylor, D.W., Patnode, H., Mishima, Y., Cheloufi, S., Ma, E., Mane, S., Hannon, G.J., Lawson, N.D., et al. (2010). A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. *Science* 328, 1694–1698.
42. Su, Z., Zhang, Y., Gendron, T.F., Bauer, P.O., Chew, J., Yang, W.Y., Fostvedt, E., Jansen-West, K., Belzil, V.V., Desaro, P., et al. (2014). Discovery of a biomarker and lead small molecules to target r(GGGGCC)-associated defects in c9FTD/ALS. *Neuron* 83, 1043–1050.
43. Stepto, A., Gallo, J.M., Shaw, C.E., and Hirth, F. (2014). Modelling C9ORF72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal dementia. *Acta Neuropathol.* 127, 377–389.

44. van Blitterswijk, M., Gendron, T.F., Baker, M.C., DeJesus-Hernandez, M., Finch, N.A., Brown, P.H., Daugherty, L.M., Murray, M.E., Heckman, M.G., Jiang, J., et al. (2015). Novel clinical associations with specific C9ORF72 transcripts in patients with repeat expansions in C9ORF72. *Acta Neuropathol.* *130*, 863–876.
45. Donnelly, C.J., Zhang, P.W., Pham, J.T., Haeusler, A.R., Mistry, N.A., Vidensky, S., Daley, E.L., Poth, E.M., Hoover, B., Fines, D.M., et al. (2013). RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. *Neuron* *80*, 415–428.
46. Shi, Y., Lin, S., Staats, K.A., Li, Y., Chang, W.-H., Hung, S.-T., Hendricks, E., Linares, G.R., Wang, Y., Son, E.Y., et al. (2018). Haploinsufficiency leads to neurodegeneration in C9ORF72 ALS/FTD human induced motor neurons. *Nat. Med.* *24*, 313–325.
47. Liu, E.Y., Russ, J., Wu, K., Neal, D., Suh, E., McNally, A.G., Irwin, D.J., Van Deerlin, V.M., and Lee, E.B. (2014). C9orf72 hypermethylation protects against repeat expansion-associated pathology in ALS/FTD. *Acta Neuropathol.* *128*, 525–541.
48. Fratta, P., Poulter, M., Lashley, T., Rohrer, J.D., Polke, J.M., Beck, J., Ryan, N., Hensman, D., Mizielinska, S., Waite, A.J., et al. (2013). Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal dementia. *Acta Neuropathol.* *126*, 401–409.
49. Liu, Y., Pattamatta, A., Zu, T., Reid, T., Bardhi, O., Borchelt, D.R., Yachnis, A.T., and Ranum, L.P. (2016). C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD. *Neuron* *90*, 521–534.
50. Liu, Y.P., Haasnoot, J., ter Brake, O., Berkhout, B., and Konstantinova, P. (2008). Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. *Nucleic Acids Res.* *36*, 2811–2824.
51. Sun, D., Melegari, M., Sridhar, S., Rogler, C.E., and Zhu, L. (2006). Multi-miRNA hairpin method that improves gene knockdown efficiency and provides linked multi-gene knockdown. *Biotechniques* *41*, 59–63.
52. Yoda, M., Cifuentes, D., Izumi, N., Sakaguchi, Y., Suzuki, T., Giraldez, A.J., and Tomari, Y. (2013). Poly(A)-specific ribonuclease mediates 3'-end trimming of Argonaute2-cleaved precursor microRNAs. *Cell Rep.* *5*, 715–726.
53. Schwarz, D.S., Hutvagner, G., Du, T., Xu, Z., Aronin, N., and Zamore, P.D. (2003). Asymmetry in the assembly of the RNAi enzyme complex. *Cell* *115*, 199–208.
54. Vitsios, D.M., Davis, M.P., van Dongen, S., and Enright, A.J. (2017). Large-scale analysis of microRNA expression, epi-transcriptomic features and biogenesis. *Nucleic Acids Res.* *45*, 1079–1090.
55. Maczuga, P., Verheij, J., van der Loos, C., van Logtstein, R., Hooijer, G., Martier, R., Borel, F., Lubelski, J., Koornneef, A., Blits, B., et al. (2014). Therapeutic expression of hairpins targeting apolipoprotein B100 induces phenotypic and transcriptome changes in murine liver. *Gene Ther.* *21*, 60–70.
56. Maczuga, P., Koornneef, A., Borel, F., Petry, H., van Deventer, S., Ritsema, T., and Konstantinova, P. (2012). Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100. *BMC Biotechnol.* *12*, 42.
57. Slezak-Prochazka, I., Durmus, S., Kroesen, B.-J., and van den Berg, A. (2010). MicroRNAs, macrocontrol: regulation of miRNA processing. *RNA* *16*, 1087–1095.
58. Guo, L., and Lu, Z. (2010). The fate of miRNA* strand through evolutionary analysis: implication for degradation as merely carrier strand or potential regulatory molecule? *PLoS ONE* *5*, e11387.
59. Diederichs, S., and Haber, D.A. (2007). Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. *Cell* *131*, 1097–1108.
60. Gagnon, K.T., Li, L., Chu, Y., Janowski, B.A., and Corey, D.R. (2014). RNAi factors are present and active in human cell nuclei. *Cell Rep.* *6*, 211–221.
61. Catalanotto, C., Cogoni, C., and Zardo, G. (2016). MicroRNA in control of gene expression: An overview of nuclear functions. *Int. J. Mol. Sci.* *17*, E1712.
62. Saraiva, J., Nobre, R.J., and Pereira de Almeida, L. (2016). Gene therapy for the CNS using AAVs: The impact of systemic delivery by AAV9. *J. Control. Release* *241*, 94–109.
63. Borel, F., Gernoux, G., Cardozo, B., Metterville, J.P.T., Toro Cabrera, G.C., Song, L., Su, Q., Gao, G.P., Elmallah, M.K., Brown, R.H., Jr., and Mueller, C. (2016). Therapeutic rAAVrh10 Mediated SOD1 Silencing in Adult SOD1^{G93A} Mice and Nonhuman Primates. *Hum. Gene Ther.* *27*, 19–31.
64. Biferi, M., Cohen-Tannoudji, M., Cappelletto, A., Giroux, B., Roda, M., Astord, S., Marais, T., Ferry, A., Voit, T., and Barkats, M. (2017). A new AAV10-mediated gene therapy for SOD1-linked ALS. *Neuromuscul. Disord.* *27* (Suppl 2), S246.
65. Dirren, E., Aebischer, J., Rochat, C., Towne, C., Schneider, B.L., and Aebischer, P. (2015). SOD1 silencing in motoneurons or glia rescues neuromuscular function in ALS mice. *Ann. Clin. Transl. Neurol.* *2*, 167–184.
66. Foust, K.D., Salazar, D.L., Likhite, S., Ferraiuolo, L., Ditsworth, D., Ilieva, H., Meyer, K., Schmelzer, L., Braun, L., Cleveland, D.W., and Kaspar, B.K. (2013). Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALS. *Mol. Ther.* *21*, 2148–2159.
67. Stoica, L., Todeasa, S.H., Cabrera, G.T., Salameh, J.S., ElMallah, M.K., Mueller, C., Brown, R.H., Jr., and Sena-Esteves, M. (2016). Adeno-associated virus-delivered artificial microRNA extends survival and delays paralysis in an amyotrophic lateral sclerosis mouse model. *Ann. Neurol.* *79*, 687–700.
68. Wang, W., Wen, D., Duan, W., Yin, J., Cui, C., Wang, Y., Li, Z., Liu, Y., and Li, C. (2018). Systemic administration of scAAV9-IGF1 extends survival in SOD1^{G93A} ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway. *Brain Res. Bull.* *139*, 203–210.
69. Mendell, J.R., Al-Zaidy, S., Shell, R., Arnold, W.D., Rodino-Klapac, L.R., Prior, T.W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017). Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. *N. Engl. J. Med.* *377*, 1713–1722.
70. Evers, M.M., Miniarikova, J., Juhas, S., Vallès, A., Bohuslavova, B., Juhasova, J., Skalnikova, H.K., Vodicka, P., Valekova, I., Brouwers, C., et al. (2018). AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model. *Mol. Ther.* *26*, 2163–2177.
71. Aschauer, D.F., Kreuz, S., and Rumpel, S. (2013). Analysis of transduction efficiency, tropism and axonal transport of AAV serotypes 1, 2, 5, 6, 8 and 9 in the mouse brain. *PLoS ONE* *8*, e76310.
72. Samaranch, L., Blits, B., San Sebastian, W., Hadaczek, P., Bringas, J., Sudhakar, V., Macayan, M., Pivrotto, P.J., Petry, H., and Bankiewicz, K.S. (2017). MR-guided parenchymal delivery of adeno-associated viral vector serotype 5 in non-human primate brain. *Gene Ther.* *24*, 253–261.
73. Trapnell, C., Pachter, L., and Salzberg, S.L. (2009). TopHat: discovering splice junctions with RNA-Seq. *Bioinformatics* *25*, 1105–1111.
74. Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M.J., Salzberg, S.L., Wold, B.J., and Pachter, L. (2010). Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat. Biotechnol.* *28*, 511–515.
75. Goff, L.A., Trapnell, C., and Kelley, D. (2012). CummeRbund: visualization and exploration of Cufflinks high-throughput sequencing data. <http://compbio.mit.edu/cummeRbund/>.
76. Robinson, J.T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E.S., Getz, G., and Mesirov, J.P. (2011). Integrative genomics viewer. *Nat. Biotechnol.* *29*, 24–26.
77. Liu, J., Hu, J., Ludlow, A.T., Pham, J.T., Shay, J.W., Rothstein, J.D., and Corey, D.R. (2017). c9orf72 Disease-Related Foci Are Each Composed of One Mutant Expanded Repeat RNA. *Cell Chem. Biol.* *24*, 141–148.

OMTN, Volume 14

Supplemental Information

Artificial MicroRNAs Targeting *C9orf72* Can Reduce Accumulation of Intra-nuclear Transcripts in ALS and FTD Patients

Raygene Martier, Jolanda M. Liefhebber, Jana Miniarikova, Tom van der Zon, Jolanda Snapper, Iris Kolder, Harald Petry, Sander J. van Deventer, Melvin M. Evers, and Pavlina Konstantinova

Supplementary material




Figure S1. Ratio of reads between C9-ALS patients and controls in cortex. The total amount of reads counted in different intronic and exonic regions from C9-ALS patients were divided by the total amount of reads from the same region of control donors.




Figure S2. Processing of miC-101 in the cell. In the canonical pathway, miC-101 is transcribed by RNA pol II and produces a primary miRNA (pri-miC) hairpin, which is processed by Drosha to generate a precursor miRNA (pre-miC). The pre-miC is transported by exportin 5 (exp 5) into the cytoplasm for further processing by Dicer to produce a miC duplex of ~20-22 basepairs. An Argonaute (Ago2) protein binds the duplex and incorporates the mature miC-101 guide strand in the RNA-induced silencing complex (RISC) to suppress downstream target gene expression. The passenger strand of the miC-101 duplex is usually discarded but can also be functional.¹




Figure S3. Processing of miC-451 in the cell. In the non-canonical pathway, miC-451 follows the same Drosha dependent processing in the nucleus into a pre-miC. The pre-miC-451 is too short to be cleaved by dicer and is directly loaded into Ago proteins. Ago2 cleaves the 3' arm of pre-miR-451 by its slicer activity and yields a ~30-nt intermediate that is further trimmed by PARN to generate a mature miC of ~23nt. The trimming of the miC-451 is not essential for efficiency and miC-451 can be functional with mature guide strands longer than the mature length.²

miC	mature miRNA (5' to 3' Guide strand)	length	reads	% reads	mature miRNA (5' to 3' passenger strand)	nt length	reads	% reads
miC2_101								
Total expression values: 1E+06								
<pre> 5' passenger u c u g g c u g u c u a g c c c a c a g u a c u c g c u g a g g g u g a c u c g g g u g u c a u g a g c g a c u c c d a d u g u a u a g g a a a a u c 3' guide </pre>								
1	TCACCTCAGCGAGTACTGTGA	22	636099	57,6%	1 ACAGTACTCGCTGAGGGTTGACG	23	11703	1,1%
2	CACCTCAGCGAGTACTGTGA	21	265198	24,0%	2 ACAGTACTCGCTGAGGGTTGAC	22	4773	0,4%
3	TCACCTCAGCGAGTACTGTG	21	73556	6,7%	3 ACAGTACTCGCTGAGGGTTGAC	20	4136	0,4%
4	CACCTCAGCGAGTACTGTGAG	22	23444	2,1%	4 ACAGTACTCGCTGAGGGTTGACT	23	4102	0,4%
5	TCACCTCAGCGAGTACTGTGT	22	21217	1,9%	5 ACAGTACTCGCTGAGGGTTGA	21	3800	0,3%
6	CACCTCAGCGAGTACTGTGAGA	23	20599	1,9%	6 ACAGTACTCGCTGAGGGTT	19	1618	0,1%
7	CACCTCAGCGAGTACTGTGAA	22	18592	1,7%	7 ACAGTACTCGCTGAGGGTTGACA	23	1042	0,1%
8	CACCTCAGCGAGTACTGTGG	20	14071	1,3%	8 CACAGTACTCGCTGAGGGTTG	21	774	0,1%
	total			97,1%		total		2,9%
miC4_101								
Total expression values: 3,40E+06								
<pre> 5' passenger u c u g g c g c u c u a g c c a c u c a g g a g u c g c g c g c u a g g g u c g g u g a g u c c u c a g c g c g c g a u c u u a u a g g u a a a u c 3' guide </pre>								
1	CTAGCGCGGACTCCTGAGTT	21	1955837	63,2%	1 CTCAGGAGTCGCGCGCTGA	19	47230	1,5%
2	CTAGCGCGGACTCCTGAGTTA	22	378744	12,2%	2 ACTCAGGAGTCGCGCGCTGA	20	5763	0,2%
3	CTAGCGCGGACTCCTGAGTTT	22	334594	10,8%	3 CTCAGGAGTCGCGCGCTG	18	5187	0,2%
4	CTAGCGCGGACTCCTGAGT	20	192640	6,2%	4 CTCAGGAGTCGCGCGCTGAGGG	22	4382	0,1%
5	CTAGCGCGGACTCCTGAGTTAA	23	81917	2,0%	5 CTCAGGAGTCGCGCGCTGAGGGT	23	3151	0,1%
6	CTAGCGCGGACTCCTGAGTTG	22	37869	1,2%	6 CACTCAGGAGTCGCGCGCTGA	21	3128	0,1%
7	CTAGCGCGGACTCCTGAGTT	22	34766	1,1%	7 CTCAGGAGTCGCGCGCTGT	19	2365	0,1%
8	TAGCGCGGACTCCTGAGTT	20	24587	0,8%	8 CTCAGGAGTCGCGCGCTGAGGGA	23	2311	0,1%
	total			97,6%		total		2,4%
miC32_101								
Total expression values: 3,46E+06								
<pre> 5' passenger u c u g g c c g u c u a g c c u c u u g g u c c u a g a g u a a g g a c u c g g a g a a c c a g g a u c u c a u u c g u u a u a g g u a a a u c 3' guide </pre>								
1	TCCTTACTCTAGGACCAAGAT	22	2606713	79,5%	1 TCTTGCTCTAGATTAACGGACG	22	24762	0,8%
2	TCCTTACTCTAGGACCAAGATT	23	268810	8,2%	2 TCTTGCTCTAGATTAACGGA	21	16762	0,5%
3	CCCTTACTCTAGGACCAAGAT	21	142674	4,4%	3 TCTTGCTCTAGATTAACGG	20	7759	0,2%
4	CCCTTACTCTAGGACCAAGATT	22	75024	2,3%	4 TCTTGCTCTAGATTAACGGA	22	6829	0,2%
5	TCCTTACTCTAGGACCAAGA	21	37463	1,1%	5 TCTTGCTCTAGATTAACGGAC	22	6535	0,2%
6	TCCTTACTCTAGGACCAAGATT	24	36928	1,1%	6 TCTTGCTCTAGATTAACG	19	6513	0,2%
7	TCCTTACTCTAGGACCAAGAC	22	16022	0,5%	7 TCTTGCTCTAGATTAACGG	21	6217	0,2%
8	TCCTTACTCTAGGACCAAGA	20	13809	0,4%	8 TCTTGCTCTAGATTAACGGACT	24	4317	0,1%
	total			97,6%		total		2,4%
miC33_101								
Total expression values: 1E+06								
<pre> 5' passenger u c u g g c g g u c u a g c c u c u u g g u c c u a g a g u a a g g c c a u c g g a g a a c c a g g a u c u c a u u c c g g u u a u a g g a a a a u c 3' guide </pre>								
1	GCCTTACTCTAGGACCAAGAT	22	304832	25,5%	1 CTTGGTCTAGAGTAAGGGCC	21	10472	0,9%
2	GCCTTACTCTAGGACCAAGA	20	260199	21,7%	2 CTTGGTCTAGAGTAAGGG	20	3471	0,3%
3	GCCTTACTCTAGGACCAAGAA	21	193939	16,2%	3 CTTGGTCTAGAGTAAGG	19	2371	0,2%
4	GCCTTACTCTAGGACCAAGATT	23	143923	12,0%	4 CTTGGTCTAGAGTAAGGGC	20	2109	0,2%
5	GCCTTACTCTAGGACCAAGACC	22	82239	6,9%	5 CTTGGTCTAGAGTAAGGGC	21	1873	0,2%
6	GCCTTACTCTAGGACCAAGAA	22	73716	6,2%	6 CTTGGTCTAGAGTAAGGGCC	22	1442	0,1%
7	GCCTTACTCTAGGACCAAGAG	22	69331	5,8%	7 CTTGGTCTAGAGTAAGGGCCA	22	1299	0,1%
8	GCCTTACTCTAGGACCAAGACT	22	44100	3,7%	8 CTTGGTCTAGAGTAAGGG	19	1184	0,1%
	total			98,0%		total		2,0%
miC46_101								
Total expression values: 2E+05								
<pre> 5' passenger u c u g g c u g u c u a g c c c u c u c g g a a c c u g a a g a u g a c u c g g g a g a a g c c u u g g a c u u c a u g g u a u a g g a a a a u c 3' guide </pre>								
1	TTATCTCTAGGTTCCGAAGAGA	22	10318	5,6%	1 TCTTGGAACTGAAGATTGACG	23	126624	68,3%
2	TTATCTCTAGGTTCCGAAGAG	21	340	0,2%	2 TCTTGGAACTGAAGATTGAC	22	16393	8,8%
3	TTATCTCTAGGTTCCGAAGAGT	22	240	0,1%	3 TCTTGGAACTGAAGATTGACGT	24	15479	8,3%
4	TTATCTCTAGGTTCCGAAGAGAA	23	199	0,1%	4 TCTTGGAACTGAAGATTGACT	23	5010	2,7%
5	TTATCTCTAGGTTCCGAAGAGA	21	198	0,1%	5 TCTTGGAACTGAAGATTGA	21	4479	2,4%
6	TTATCTCTAGGTTCCGAAG	19	151	0,1%	6 TCTTGGAACTGAAGATTGACGCTATTCTAAAG	35	2069	1,1%
7	TTATCTCTAGGTTCCGA	17	144	0,1%	7 TCTTGGAACTGAAGATTGACGTT	25	1939	1,0%
8	TTATCTCTAGGTTCCGAA	18	105	0,1%	8 CTCTGGAACTGAAGATTGACG	22	1779	1,0%
	total			6,3%		total		93,7%
miC49_101								
Total expression values: 3,70E+05								
<pre> 5' passenger u c u a g c c g u c u a g c c a g c u u g a a c u a g g a u g a g u c u u c g g u c g a a c c u u g a u c c a u c c g g g u a u a g g c a a a u c 3' guide </pre>								
1	GCTCCTCTATGTTCAAGCTCG	22	142575	42,9%	1 AGCTTGAACATAGGATGACGTC	22	73189	22,0%
2	CTCCTCTATGTTCAAGCTCG	21	34782	10,5%	2 AGCTTGAACATAGGATGACGT	21	14962	4,5%
3	GCTCCTCTATGTTCAAGCTCT	22	21281	6,4%	3 AGCTTGAACATAGGATGACGTC	23	8609	2,6%
4	CTCCTCTATGTTCAAGCTCGG	22	5304	1,6%	4 GCTTGAACATAGGATGACGTC	21	6126	1,8%
5	GCTCCTCTATGTTCAAGCTC	21	4672	1,4%	5 AGCTTGAACATAGGATGACG	20	4119	1,2%
6	GCTCCTCTATGTTCAAGCTCGT	23	4018	1,2%	6 AGCTTGAACATAGGATGACGTC	23	2509	0,8%
7	CTCCTCTATGTTCAAGCTCGA	22	3894	1,2%	7 CAGCTTGAACATAGGATGACGT	22	2150	0,6%
8	GCTCCTCTATGTTCAAGCTCGA	23	3608	1,1%	8 AGCTTGAACATAGGATGACGTT	22	905	0,3%
	total			66,2%		total		33,8%
miC50_101								
Total expression values: 1E+06								
<pre> 5' passenger u c u g g c c g u c u a g c c a u a c u a c c u u g u a g u d c c u c u c g g u a u g a u g g a a c a u c a c a g g g a g u a u a g g u a a a u c 3' guide </pre>								
1	AGGGACACTACAAGGTAGTATT	22	455665	35,7%	1 TACTACCTTGTAGTGTCCCCCTCG	23	349594	27,4%
2	AGGGACACTACAAGGTAGTAT	21	73542	5,8%	2 TACTACCTTGTAGTGTCCCCCTCGT	24	85200	6,7%
3	AGGGACACTACAAGGTAGTA	20	15195	1,2%	3 TACTACCTTGTAGTGTCCCCCTC	22	65164	5,1%
4	GGGACACTACAAGGTAGTATT	21	12306	1,0%	4 TACTACCTTGTAGTGTCCCCCTC	23	62606	4,9%
5	AGGGACACTACAAGGTAGTATT	23	9717	0,8%	5 TACTACCTTGTAGTGTCCCCCTCGA	24	61009	4,8%
6	AGGGACACTACAAGGTAGTATTA	23	5461	0,4%	6 TACTACCTTGTAGTGTCCCCCTC	21	38667	3,0%
7	GGGACACTACAAGGTAGTATTG	22	3372	0,3%	7 ATACTACCTTGTAGTGTCCCCCTC	24	20936	1,6%
8	GGGACACTACAAGGTAGTAT	20	2861	0,2%	8 TACTACCTTGTAGTGTCCCCCTCGTT	25	15182	1,2%
	total			45,3%				54,7%

Table S1. miC-101 processing by NGS. Sequence distribution (%) of guide- and passenger strands of reads mapping to miC2_101, miC4_101, miC32_101, miC33_101, miC46_101, miC49_101 and miC50_101. Human embryonic kidney (HEK)293T cells were transfected with 250ng of the constructs. RNA was isolated 48 hours post-transfection and small RNA NGS was performed. The scaffold for each candidate is shown in the first column. Based on miRBase, the predicted guide and passenger strand sequences of the cellular pri-

miRNA scaffolds are indicated in red and blue, respectively. The 5' and 3' flanking nucleotides are indicated in black.

miC	mature miRNA (5' to 3' Guide strand)	length	reads	% reads
miC38_451				
Total expression values: 6,21E+04				
5'	guide			
c	a g a			
u u g g g a u g g c a a g	g c a a u c u c u g u c u u g g c			
g a c c c u a u c g u u c	c g u u a g a g a c a g a a c c g			
a	a u c			
3'				
1	AGCAATCTCTGTCTTGGCAACAGCC	25	12263	22,2%
2	AGCAATCTCTGTCTTGGCAACGCCAT	27	11500	20,8%
3	AGCAATCTCTGTCTTGGCAACGCCAAT	28	7931	14,3%
4	AGCAATCTCTGTCTTGGCAACGCCAAGA	29	4655	8,4%
5	AGCAATCTCTGTCTTGGCAACGCCAAG	28	3896	7,0%
6	AGCAATCTCTGTCTTGGCAACGCCAA	27	2978	5,4%
7	AGCAATCTCTGTCTTGGCAACGCCCT	26	2973	5,4%
8	AGCAATCTCTGTCTTGGCAACAGC	23	2773	5,0%
9	AGCAATCTCTGTCTTGGCAACGCCATT	28	2732	4,9%
10	AGCAATCTCTGTCTTGGCAACGCCAAGT	29	1779	3,2%
11	AGCAATCTCTGTCTTGGCAACGCCAAA	28	1048	1,9%
12	AGCAATCTCTGTCTTGGCAACA	22	805	1,5%
	total			100,0%
miC39_451				
Total expression values: 2,05E+05				
5'	guide			
c	a g u			
u u g g g a u g g c a a g	a a a g c a a u c u c u g u c u u			
g a c c c u a u c g u u c	u u u c g u u a g a g a c a g a a			
a	a u c			
3'				
1	TAAAGCAATCTCTGTCTTGGCA	22	76916	39,1%
2	TAAAGCAATCTCTGTCTTGGCAA	23	75442	38,4%
3	TAAAGCAATCTCTGTCTTGGCAA	24	13838	7,0%
4	TAAAGCAATCTCTGTCTTGGCAAAG	25	11180	5,7%
5	TAAAGCAATCTCTGTCTTGGC	21	6379	3,2%
6	TAAAGCAATCTCTGTCTTGGCAAT	24	2638	1,3%
7	AAAGCAATCTCTGTCTTGGCAA	22	2314	1,2%
8	TAAAGCAATCTCTGTCTTGGCAAAGA	26	2238	1,1%
9	TAAAGCAATCTCTGTCTTGGCAT	23	1613	0,8%
10	AAAGCAATCTCTGTCTTGGCA	21	1502	0,8%
11	AAAGCAATCTCTGTCTTGGCAAAG	24	1248	0,6%
12	TAAAGCAATCTCTGTCTTGGCAAAGT	26	1243	0,6%
	total			99,9%
miC43_451				
Total expression values: 1,36E+04				
5'	guide			
c	a g u			
u u g g g a u g g c a a g	u g g c a a g a a a a g u u a u u			
g a c c c u a u c g u u c	a c c g u u c u u u u c a a u a a			
a	a u c			
3'				
1	TTGGCAAGAAAAGTTATTTCTCAAT	25	5312	42,7%
2	TTGGCAAGAAAAGTTATTTCTCAATAACT	29	1853	14,9%
3	TTGGCAAGAAAAGTTATTTCTCA	23	1387	11,1%
4	TTGGCAAGAAAAGTTATTTCTCAATAAC	28	1253	10,1%
5	TTGGCAAGAAAAGTTATTTCTCAATA	26	1015	8,2%
6	TTGGCAAGAAAAGTTATTTCTCAATAACTT	30	556	4,5%
7	TTGGCAAGAAAAGTTATTTCTCAA	24	525	4,2%
8	TTGGCAAGAAAAGTTATTTCTCAATAA	27	272	2,2%
9	TTGGCAAGAAAAGTTATTTCTC	22	228	1,8%
10	TTGGCAAGAAAAGTTATTTCT	23	54	0,4%
11				0,0%
12				0,0%
	total			100,0%
miC49_451				
Total expression values: 1,37E+05				
5'	guide			
c	a g a			
u u g g g a u g g c a a g	g c u c a u c c u a u g u u c a a			
g a c c c u a u c g u u c	c g a g u a g g a u c a a g u u			
a	a u c			
3'				
1	AGCTCATCCTATGTTCAAGCTCTT	24	76725	58,6%
2	AGCTCATCCTATGTTCAAGCTCTTG	25	14652	11,2%
3	AGCTCATCCTATGTTCAAGCTCTTGA	26	13511	10,3%
4	AGCTCATCCTATGTTCAAGCTCT	23	11970	9,1%
5	AGCTCATCCTATGTTCAAGCTCTTGAAC	28	6402	4,9%
6	AGCTCATCCTATGTTCAAGCTCTTGT	26	2060	1,6%
7	AGCTCATCCTATGTTCAAGCTCTTGAA	27	1982	1,5%
8	AGCTCATCCTATGTTCAAGCTCTTT	25	1321	1,0%
9	AGCTCATCCTATGTTCAAGCTCTTGAACA	29	693	0,5%
10	GCTCATCCTATGTTCAAGCTCTT	23	634	0,5%
11	AGCTCATCCTATGTTCAAGCTCTTA	25	534	0,4%
12	AGCTCATCCTATGTTCAAGCTCTTGAT	27	406	0,3%
	total			100,0%
miC50_451				
Total expression values: 1,06E+04				
5'	guide			
c	a g u			
u u g g g a u g g c a a g	g g g a c a c u a c a a g g u a g			
g a c c c u a u c g u u c	c c c u g u g a u g u u c c a u c			
a	a a u			
3'				
1	TGGGACACTACAAGGTAGTATTCTACCTT	29	5354	55,9%
2	TGGGACACTACAAGGTAGTATTCTACCT	28	961	10,0%
3	TGGGACACTACAAGGTAGTATT	22	611	6,4%
4	TGGGACACTACAAGGTAGTATTC	23	560	5,8%
5	TGGGACACTACAAGGTAGTATTCTACCTTT	30	485	5,1%
6	TGGGACACTACAAGGTAGTATTCTACCTTG	30	461	4,8%
7	TGGGACACTACAAGGTAGTATTCT	24	284	3,0%
8	TGGGACACTACAAGGTAGTATTCTACC	27	274	2,9%
9	TGGGACACTACAAGGTAGTATTCTACCTTGT	31	252	2,6%
10	TGGGACACTACAAGGTAGTATTCTACCTTA	30	149	1,6%
11	TGGGACACTACAAGGTAGTATTCTACCTA	29	126	1,3%
12	GGGACACTACAAGGTAGTATTCTACCTT	28	73	0,8%
	total			100,0%

Table S2. miC-451 processing by NGS. Sequence distribution (%) of guide strands of reads mapping to miC38_451, miC39_451, miC43_451, miC49_451 and miC 50_451.

Performed as described in table S1.

References

1. Miniarikova, J, Zanella, I, Huseinovic, A, van der Zon, T, Hanemaaijer, E, Martier, R, *et al.* (2016). Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease. *Mol. Ther. Nucleic Acids* **5**: e297.
2. Mayuko Yoda, Daniel Cifuentes, Natsuko Izumi, Yuriko Sakaguchi, Tsutomu Suzuki, AJG and YT (2013). PARN mediates 3'-end trimming of Argonaute2-cleaved precursor microRNAs **5**.